NEUROENHANCEMENT: STATE OF THE ART AND FUTURE PERSPECTIVES

Donatella Marazziti, Maria Teresa Avella, Tea Ivaldi, Stefania Palermo, Lucia Massa, Alessandra Della Vecchia, Lucia Basile, Federico Mucci

Abstract

Pharmacological neuroenhancement refers to the non-medical use of prescription drugs, alcohol, illegal drugs, or the so-called soft enhancers for the purpose of improving cognition, mood, pro-social behavior, or work and academic performance. This phenomenon is undoubtedly more frequent than previously supposed especially amongst university students. The aim of the present paper was to carefully review and comment on the available literature on neuroenhancement, according to Prisma guidelines. The results showed a great use of all prescribed drugs (benzodiazepines, antidepressants, antipsychotics, nootropic compounds, and especially stimulants) as neuroenhancers amongst healthy subjects, although probably the real prevalence is underestimated. The use of illicit drugs and soft enhancers is similarly quite common. Data on the improvement of cognition by other compounds, such as oxytocin and pheromones, or non-pharmacological techniques, specifically deep brain stimulation and transcranial magnetic stimulation, are still limited. In any case, if it is true that human beings are embedded by the desire to overcome the limits of their intrinsic nature, neuroenhancement practices put into question the concept of authenticity. Therefore, the problem appears quite complex and requires to be deepened and analyzed with no prejudice, although within an ethical conceptual frame.

Key words: neuroenhancement, drugs, university students

Donatella Marazziti1,2, Maria Teresa Avella1, Tea Ivaldi1, Stefania Palermo1, Lucia Massa1, Alessandra Della Vecchia1, Lucia Basile1, Federico Mucci2

1 Department of Clinical and Experimental Medicine, Section of Psychiatry, University of Pisa, Via Roma, 67 56100 Pisa, Italy
2 Unicamillus-Saint Camillus International University of Health Sciences, Rome, Italy
3 Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Italy

Introduction

Pharmacological neuroenhancement, or cognitive neuroenhancement, refers to the non-medical use of prescription drugs, alcohol or illegal drugs, or of the so-called soft enhancers, such as food supplements (e.g., herbal sedatives, vitamins and tonics), caffeine-containing products, energy drinks, and no-prescription drugs available in drug stores, to enhance cognition, mood, work or school performance, or to promote pro-social behavior (Gründer & Bartsch, 2014; Weiergräber et al., 2017). According to some authors (Middendorff et al., 2017), soft enhancers should not be included in the neuroenhancer category, although their use is quite common especially amongst students (Dietz et al., 2018; Micoulaud-Franchi et al., 2014).

Emotional enhancement is another category of neuroenhancement aiming at modifying an individual’s emotions by amplifying and/or enhancing emotional states beyond normal levels of intensity by artificial means. It is noteworthy to underline that emotional enhancement does not induce actively specific emotions, but, on the contrary, it works by passively amplifying and enhancing the genuine (positive or negative) emotions that usually a person feels before using the enhancer (Kraemer, 2011).

Some authors consider neuroenhancement a sort of an umbrella term referring to different types of interventions whose target is to improve human capacities beyond normal limits, and perhaps as means helping individuals to find their authenticity. According to this notion, it does not recognize any medical targets, because its purpose is to ameliorate wellbeing and consequently quality life of healthy individuals (Gordijn, 2015; Juengst, 1998).

Currently, there are no reliable data about the worldwide prevalence of neuroenhancement practice, for the real difficulties to describe and assess such a phenomenon. Generally, it is inferred from the consumption of non-medical use of prescription drugs, although to differentiate between occasional and more regular use may be quite challenging (Ragan et al., 2013). Students represent a population endowed with a particular risk for possible use of neuro-enhancing substances (Greely et al., 2008; Sahakian & Morein-Zamir, 2007). According to available data, between 5 and 35% of American or Canadian students use neuroenhancers and specifically 2-5% at least once a month and 1-3%
once a week (Outram, 2010), with a constant and progressive increase from high schools to college (McCabe et al., 2005; Wilens et al., 2008). Data in both Europe and Australia report a lower incidence than in the USA or Canada (Eickenhorst et al., 2012; Franke et al., 2011; Maier et al., 2013; Partridge et al., 2013). The difference between USA and European/Australian data is that North-American students have to cope with highly competitive academic contexts, and easily indulge to booster cognitive skills during exams, or to regulate mood, stress or anxiety symptoms that could indirectly impair performances (Lucke et al., 2018; Weyandt et al., 2009).

It should be noted, however, that studies on the prevalence of neuroenhancers show different limitations, so that the conclusions should be taken with caution. First, most of them are carried out on volunteers, thus implying a selection bias: indeed, subjects using neuroenhancers tend to be too confident on their effects and might influence study outcomes. This gap between perceived benefits and results observed yawns even wider in real-life conditions: 70% of methylphenidate (MPH) users report a positive or very positive effect, so that, not surprisingly, the heavier consumers are those with highest satisfaction scores. Second, the studies are rarely double-blinded and placebo-controlled. Third, they tend to investigate the effect of a substance after a single dose, while information about a repeated use is lacking (National Consultative Ethics Committee for Health and Life Sciences, CCNE, 2013). This may be due to the fact that the prolonged administration of potentially dangerous substances to healthy subjects implies different ethical issues and the epidemiological studies are the only accepted (Heinz et al., 2012). Fourth, just a few studies investigated the reasons for taking the neuroenhancer. In any case, available data are considered unreliable and able to identify only the tip of the iceberg, given the under-reported consumption of neuroenhancers (Wilens et al., 2008).

Drugs that enhance one type of function might have a detrimental impact on another, or people who already function well might not experience any benefit, whereas those with less natural ability might experience only modest effects (Normann & Berger, 2008; Weiergräber et al., 2017). Another important issue is whether statistically significant improvements in cognitive functioning can be translated into practical or clinically significant benefits in real-world contexts. Notwithstanding these caveats, some proponents of neuroenhancement speculate that it will soon become a normal practice, although such a hypothesis is supported by limited evidence.

Furthermore, little is known about possible risk for health of neuroenhancers, being abuse and/or addiction one the major potential risk at least in vulnerable subjects, as neuroenhancers interact with the dopaminergic system (Heinz et al., 2012).

The aim of this paper is to review and comment on current literature on neuroenhancement and, to a lesser extent on emotional enhancement, with some personal and ethical considerations on this topic.

Materials and Methods

According to the PRISMA guidelines (Moher et al., 2009), the databases of PubMed, Scopus, Embase, PsycINFO and Google Scholar were accessed in order to research and collect articles that were published only in English language from 1980 to April 2020. Free text terms and MeSH headings were combined as it follows: “(neuroenhancement OR emotional enhancement) AND (antidepressants OR benzodiazepines OR antipsychotics OR nootropics OR stimulants OR methylphenidate OR amphetamines OR modafinil OR atomoxetine OR piracetam OR acetyl-cholinesterase inhibitors OR cannabinoids OR hallucinogens OR alcohol OR caffeine OR gingko biloba OR hypericum OR oxytocin OR pheromones)". All the authors agreed to include in the review conference abstracts, posters and case reports if published in indexed journals. The following inclusion criteria were adopted: studies carried out in clinical samples of adults; reliable diagnosis of psychiatric disorders according to structured interviews and standardized criteria; reliable assessment of outcome measures. All the authors equally contributed in identifying potential information specific to this topic amongst the titles and abstracts of the publications. The first selection excluded 10821 titles because: a) duplicates; b) not concerning the scope of the paper; c) not informative enough. The second selection excluded 509 abstracts after being read and reviewed, as the information reported did not fulfill the scope of our paper and/or the presented information did not seem relevant to the discussed topic. Subsequently, 293 more publications were excluded after being completely read and evaluated, as they did not provide enough information and/or resulted sufficiently in line with our review. Finally, 123 papers were included in the present review (figure 1).

Discussion

Neuroenhancement

As already underlined above, neuroenhancement is mostly pharmacological and includes the non-medical use of prescribed drugs, such as benzodiazepines (BDZ) antidepressants (ADs), antipsychotics, prescribed stimulants and nootropic compounds, and of smart or illegal drugs (de Jongh et al., 2008; Maier & Schaub, 2015). Non-pharmacological techniques, including deep brain stimulation (DBS) and transcranial magnetic stimulation (TMS) may also improve cognitive functions. Therefore, all these compounds and techniques will be described herein.

Benzodiazepines

Benzodiazepines are used as emotional enhancers thanks to their relaxant and anxiolytic activity. This class of drugs became extremely popular in the 1970s, since they represented a real advancement, as compared with barbiturates, given their relatively safety in overdose. In particular, diazepam (Valium) led to a so-called “Valium-mania”, as it was increasingly used not only for anxiety disorders, but also to deal with everyday life problems, so that it became the most prescribed drug of any types of the seventies (Calcaterra & Barrow, 2014). However, although their benefits remain unequivocal if correctly used, the popularity of BDZs slightly decreased after the mounting evidence of their adverse side effects, including severe seizures and withdrawal symptoms after abrupt discontinuation, or attention deficits, memory impairments, sleepiness and abuse/addiction in the long-term use (Panes et al., 2020; Pieters & Snelders, 2009).

In any case, different data indicate that BDZs are still quite used for their sedating properties for the purpose of neuroenhancement, as it is believed that a quieter and better sleep can improve performance, especially amongst students, as they are convinced that a relaxed brain is more efficient (Mache et al., 2012; Maier et al., 2013).
Neuroenhancement: state of the art and future perspectives

Antidepressants

Antidepressants are a class of drugs indicated not only for depression, but also for several other psychiatric conditions, including anxiety disorders, obsessive-compulsive (OCD) spectrum disorders, eating disorders, premenstrual syndrome, or pain syndromes, and several other (Cascade et al., 2007; Hofmeister & Boddien, 2016; Kennedy et al., 2016; Pratt et al., 2017). Not surprisingly they are also abused by an increasing number of healthy individuals (Normann & Berger, 2008).

Fluoxetine (Prozac), a selective serotonin reuptake inhibitor (SSRI), was marketed in 1984 and, after a few years, it became known a sort of “miracle drug”, since it was thought as able to reduce negative feelings, induce a general state of psychic well-being and improve social performance even in non-depressed individuals. In 1994 Prozac was the second most-sold drug worldwide (“Prozac-mania”) (Elliott, 2000). According to the American psychiatrist Peter Kramer, Prozac was more than an AD, it was rather a drug that could help people to find their real self and, in other words and ultimately, authenticity (Kramer, 1993). However, Kramer himself underlined that the drug should be used only when necessary, that is to say in depressed patients, so that the ensuing mood increase was with no doubt useful in those individuals who could experience a real change in their life, as they were not suffering any more.

The evidence for the use of ADs in healthy control subjects is limited, even because this phenomenon is mainly hidden. Some studies indicate that ADs may influence emotional processing in healthy individuals by increasing recognition and recall of positive emotions and reducing salience of negative affects (Harmer et al., 2003a; Harmer et al., 2004). Indeed, ADs were found to attenuate the activity of subcortical limbic neural regions during exposition to negative emotional stimuli (Bigos et al., 2008; Del-Ben et al., 2005; Harmer et al., 2006; McKie et al., 2005; Takahashi et al., 2005). A study evaluated participants’ ability to correctly detect subtle expressions of sadness and the results showed that duloxetine (SNRI) might reduce accurate recognition of sadness (Barnford et al., 2015). In another study, volunteers who received a single i.v. dose of citalopram (another SSRI) recognized more facial expressions of happiness and fear than those who had taken placebo, while no differences were observed in the recognition of other basic emotions (Harmer et al., 2003b). Subsequently, a 7-day double-blind trial carried out in healthy volunteers (n=42) treated with citalopram (20 mg/day), reboxetine (a norepinephrine-serotonin reuptake blocker) at a dose of 8 mg/day, SNRI), or placebo, highlighted that both citalopram and reboxetine decreased the identification of the negative facial expressions of anger and fear, while enhancing the relative recall of positive emotional material (Harmer et al., 2004). In any case, the available literature indicates that there is no evidence of any effect of ADs on the mood of healthy individuals (Normann & Berger, 2008). Furthermore, these compounds were found to cause emotional blunting, a syndrome which is totally different from apathy, in a significant percentages (30-40 %) of the cases in the long-term use (Marazziti, 2017; Price et al., 2009; Sansone & Sansone, 2010; Wongpakaran et al., 2007). Again, it is still an unresolved issue whether or not ADs, particularly SSRIs, may or may not impair or improve some cognitive domains (Marazziti et al., 2019). According to some authors, cognitive impairment would represent real effects of SSRI (Fava et al., 2006; Popovic et al., 2015), although, a recent meta-analysis reported that all ADs would produce positive and significant effects on control and executive functions (Rosenblat et al., 2015). However, further and focused studies are necessary to disentangle some AD side effects from effective symptom improvement that might be positive for patients (table 1).

Antipsychotics

Antipsychotics (As) are a class of psychotropic drugs primarily used in the treatment of psychoses, mainly schizophrenia and bipolar disorders, although they are increasingly being utilized for treatment of non-psychotic disorders (Huhn et al., 2019; Stahl, 2013). Due to their tranquilizer effects, their use amongst healthy individuals is not uncommon. It should be noted that the majority of data refers to first-generation antipsychotics (FGAs) (Gao et al., 2006; Pies, 2009), while information on second-generation antipsychotics (SGAs) is still limited (Miller, 2004). SGAs are often used with other illegal substances, being quetiapine the most abused, followed by olanzapine, risperidone and aripiprazole (Murphy et al., 2008; Reeves, 2007). Usually, antipsychotics are taken without proper medical indication and alcohol. Users reported combining As and other psychotropic compounds for different reasons, such as to recover from other drugs’ excessive effects, particularly excitation, or for their sedating effects, or simply as an experiment. Both positive and negative emotional effects are reported, such as feeling happy, friendly and sexy, as well as depressed, anxious and irritable (Makelshahi et al., 2015) (table 1).

Prescribed stimulants

Stimulants such as methylphenidate (MPH), modafinil, dextroamphetamine and mixed-amphetamine salts (MAS), may increase vigilance, arousal and motivation, through their pharmacological effects on norepinephrine and dopamine systems. Methylphenidate is prescribed worldwide for ADHD. Modafinil is a wakefulness-promoting agent used to treat narcolepsy, sleep apnea and shift-work sleep disorder, and even ADHD in a limited number of cases. Dextroamphetamine and MAS are also used for ADHD and narcolepsy (Mucci et al., 2019; National Institutes of Diabetes and Digestive and Kidney Diseases, NIDDK, 2012; Sharbaf Shoar et al., 2020; Thorpy & Bogan, 2020).

Not surprisingly, given their activating effects, stimulants are increasingly misused by healthy people, especially by youth and college students, or managers to enhance academic performances (McCabe et al., 2005). However, their abuse in these populations without ADHD diagnosis is a current concern, as it is estimated that about 30 % of specific prescriptions are used for neuroenhancement. The problem is particularly relevant in the USA, where, according to the National Surveys on Drug Use and Health between 2015 and 2016, 6.6% of the adult USA population (approximately 16.0 million) used prescription stimulants, with 1.9% reporting to misuse them, and 0.2% diagnosed with stimulant use disorder. Particularly, 31.2% of stimulant users referred to have misused stimulants at least once, over the preceding 12 months. Amongst motivations reported for misuse, the most common was to increase alertness and concentration (56.3%), followed by to help studying (21.9%) and to get high, adjust other drug effects, or just to experiment (15.5%), and weight loss (4.1%) (Compton et al., 2018).

These prevalence rates are quite astonishing while
considering that effective stimulating activity of stimulants on cognitive performances in healthy individuals are still a matter of debate. However, enhancer users tend to believe that stimulants improve both motivation and cognition, as reported in a study conducted amongst undergraduates of the University of Pennsylvania (n=40) with no history of ADHD (Ilieva & Farah, 2013). Indeed, although a few data indicated that MPH and modafinil might exert a certain positive influence on visuo-spatial memory and attention (Repantis et al., 2010), no direct effect on specific cognitive domains, such as memory or executive functions, has been yet demonstrated (Bagot & Kaminer, 2014; de Jongh et al., 2008; Wood et al., 2013). Interestingly, stimulants seem to increase cognitive performance in subjects with low baseline skills, while showing an opposite effect in those with higher baseline skills (Mattay et al., 2000; Mattay et al., 2003; Mehta et al., 2000; Müller et al., 2004; Randall et al., 2005).

If MPH was found not to exert a significant effect on mood and emotions (Spencer et al., 2005), modafinil seems to produce a general mood elevating effect with a simultaneous increase of negative affect and increased reactivity to fearful faces (Schmidt et al., 2017).

In the UK, a study investigating the non-medical use of stimulants among college students of 23 universities of the Russell Group, found that lifetime prevalence use of modafinil, MPH and amphetamine-dextroamphetamine was, respectively, 8%, 5.9%, and 3.2%, with 20% of the total sample reporting being interested in using stimulants for neuroenhancement. Although cognitive enhancement was the most common reason for using stimulants (approximately three quarters of cases), as expected, other reasons include tackling sleep deprivation, enhancing mood or simply for “curiosity” (Singh et al., 2014). Another study, conducted on a larger sample of academic students (n=6,725) of three different Swiss universities, reported that lifetime prevalence use of MPH and modafinil was 5.8% and 0.4%, respectively, whereas the use for neuroenhancement was, respectively, of 4.1% and 0.3% (Maier et al., 2013). Lower prevalence of use of stimulants for non-medical purposes was reported among Dutch university students. Indeed, only 2.5% of the sample (n=1,572), reported to use MPH as cognitive enhancer, with 2.8% of participants using MPH for non-medical reasons. (Schelle et al., 2015). An Italian study conducted on university students from Northern Italy (n=899) found that 11.3% of the sample took stimulants for non-medical use (MPH or amphetamine) especially if younger, with no gender difference (Majori et al., 2017) (table 2).

### Table 1. Use of antidepressants and antipsychotics as neuroenhancers

| Authors and year | Type | N | Antidepressant | Method | Results |
|------------------|------|---|----------------|--------|---------|
| Bamford et al., 2015 | Randomized controlled trial | 40 | Duloxetine | Generalised Anxiety Disorder Screener (GAD-7), visual analogue scales ranging, positive and negative affect, Cambridge Cognition Emotion Recognition Task | ↓ accurate recognition of sadness |
| Harmer et al., 2003b | Clinical trial | 24 | Citalopram | The facial expression recognition task featured five basic emotions taken from the Ekman and FriesenPictures of Affect Series | ↑ recognition of facial expressions of happiness and fear ± for the other basic emotions |
| Harmer et al., 2004 | Double-blind trial | 42 | Citalopram, reboxetine | Facial Expression Recognition, Emotional Categorization Task, Emotional Memory, Emotion-Potentiated Startle Response | ↓ identification of the negative facial expressions of anger and fear ↑ relative recall of positive emotional material |
| Rosenblat et al., 2015 | Systematic review and meta-analysis | - | Antidepressants | Trials published prior to April 15, 2015, were identified through searching the Cochrane Central Register of Controlled Trials, PubMed, Embase, PsychINFO | ↑ control and executive functions |
| Reeves, 2007 | Case-report | A 25-year old man with bipolar disorder | Olanzapine | Olanzapine abuse |
| Murphy et al., 2008 | Case report | A 29-year old man | Quetiapine | Abuse of quetiapine in a man with an unclear psychiatric history |
| Miller, 2004 | Cross-sectional | 429 inpatients for addiction | Quetiapine, olanzapine, risperidone, aripiprazole | Lifetime abuse of antipsychotics (17%), past year abuse (9.1%); quetiapine (96.0 %), olanzapine (28.0%), risperidone (20.0%) and aripiprazole (20.0%) |
| Authors and year          | Type                                           | N     | Stimulant          | Method                                      | Results                                                                 |
|--------------------------|------------------------------------------------|-------|--------------------|---------------------------------------------|-------------------------------------------------------------------------|
| Hanson et al., 2013      | Cross-sectional                                |       | Adderall           | Tweets from likely students containing GPS data were identified with clusters of nearby colleges and universities for regional comparison | 213633 tweets from 132099 unique user accounts mentioned “Adderall” Rates of Adderall tweeters were highest among college and university clusters in the northeast and south regions of the United States. |
| Singh et al., 2014       | Cross-sectional                                | 877   | Adderall           | Online survey                               | 1.4% of participants with history of occasional Adderall use, 0.3% with past regular use, 0.3% current use |
| Palamar & Le, 2017       | Cross-sectional                                | 24740 | Adderall, Amphetamine | Self-report survey                          | 6.9% and 7.9% with past year use of Adderall and amphetamine, respectively |
| Lucke et al., 2018       | Cross-sectional                                | 1136  | Adderall, Atomoxetine, Modafinil, Adderall, Ritalin | Online survey                               | Modafinil lifetime use 2.7%, past month use 1.5%, Adderall 2.9% and 1.0%, Ritalin 2.6% and 0.9%, Atomoxetine 0.1% and 0.0%, respectively |
| Teodorini et al., 2020   | Cross-sectional                                | 219   | Modafinil          | Online Survey                               | Most common reasons were “to increase attention”, “to work long hours”, “to get more done”, “exam”, “night work”, “to think more clearly”, and “other” |
| Ilieva & Farah, 2013     | Cross-sectional                                | 40    | Adderall, Ritalin and other | Online survey | ↑ perception of motivation and cognition |

| Authors and year          | Type                                           | N     | Stimulant                  | Method                                                                 | Results                                                                 |
|--------------------------|------------------------------------------------|-------|---------------------------|------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Weyandt et al., 2018     | Double-blind, placebo-controlled, within subjects crossover design trial | 13    | Adderall                  | Digit Span Forward and Backward, Story Recall subtest from the Woodcock Johnson–III, Conners Continuous Performance Test Third Edition (CPT 3), The Behavior Rating Inventory of Executive Function, Adult version (BRIEF-A), Gray Oral Reading Tests–Fifth Edition (GORT-5), Perceived Drug Effect Self-Report (PDE-SR) | ↑ attention ↓ working memory |
| Chamberlain et al., 2006 | Double-blind, placebo-controlled trial         | 60    | Adderall                  | Go trials, Probabilistic learning task                                 | ↑ response inhibition; ↔ probabilistic learning |
| Graf et al., 2011        | Double-blind, placebo-controlled trial         | 12    | Amphetamine               | Go/NoGo-Eriksen flanker paradigm, fMRI                                   | ↑ neural sensitivity for error; ↓ inhibitory control |
| Rapoport et al., 1980    | Double-blind, crossover design trial           | 31    | Adderall                  | Activity test, Skin-conductance reaction time test, Rosvold’s Continuous Performance Test (CPT) 2, Learning task, Speech Communication Task | ↑ vigilance, speech communication ↑ cues recall and free recall ↓ motor activity ↑ subjective euphoria and energy (dose-dependent effect). |
Another trial on healthy volunteers reported that MPH (20 or 40 mg) might exert a positive impact on declarative memory consolidation, and improve set shifting and stop signal tasks performance, with no effect on spatial and working memory or planning (Linssen et al., 2012). Additionally, consistent evidence suggests that MPH increases motivation in healthy individuals (Volkow et al., 2004), or response latency shifts compared with placebo (Rogers et al., 1999).

**Modafinil**

Baranski & Pigeau, 2007  
Randomized, double-blind, placebo-controlled trial  
41  
300 mg (MOD)  
20 mg (d-AMP)  
Visual judgement task  
Complex mental addition task  
↓ self-monitoring (MOD)  
↔ self-monitoring (d-AMP)

Muller et al., 2004  
Randomized, double-blind, placebo-controlled, crossover design trial  
16  
200 mg  
Cognitive task  
↓ error rates in the visual-spatial task

Turner et al., 2003  
Randomized, double-blind, placebo-controlled trial  
60  
100 or 200 mg  
CANTAB battery  
↑ recall, visual memory, spatial planning  
↑ perceived alertness and energy

Marchant et al., 2009  
Double-blind, placebo-controlled trial  
24  
200 mg  
Attention shift task  
Prospective memory task  
↑ attention-shifting tasks  
↑ prospective memory

administered methylphenidate (20 or 40 mg) and tested using a CANTAB battery in two different moments (Elliott et al., 1997). Half of the participants took MPH at the first evaluation and placebo at the second, while others the reverse. The first group obtained significant improvement in spatial working memory tasks, and reported a lower number of errors than the second group. Furthermore, the first group obtained more accurate results in the Tower of London, while the second group experienced a decrease in performance accuracy and response latencies were decreased. These results demonstrated that MPH may enhance spatial function in novel performance, while impairs consolidated performance. Participants reported to feel significantly more alert and less tired. No impact of MPH on attention and fluency emerged, since there were no differences between the two groups in attentive set-shift tasks and verbal fluency subtests. Other controlled studies support the hypothesis that MPH can enhance cognitive ability. As demonstrated by a randomized, double-blind, placebo-controlled, crossover design study, MPH improved the capacity of detecting performance errors in healthy individuals, even after a single dose (30 mg) (Elliott et al., 1997). Another trial on healthy volunteers reported that MPH (20 or 40 mg) might exert a positive impact on declarative memory consolidation, and improve set shifting and stop signal tasks performance, with no effect on spatial and working memory or planning (Linssen et al., 2012). Additionally, consistent evidence suggests that MPH increases motivation in healthy individuals (Volkow et al., 2004), or response latency shifts compared with placebo (Rogers et al., 1999).

**Modafinil**

Different studies explored whether or not modafinil might improve cognitive ability in healthy individuals. A double-blind, placebo-controlled study on 24 healthy university students demonstrated that modafinil (200 mg) might enhance attention-shifting tasks, with no impact on task implying unpredictable and infrequent disengagement of attention emerged, as well as prospective memory (Marchant et al., 2009). These results were partially confirmed by another research on adult male volunteers (n=60) administered with a single...
dose of modafinil (100 or 200 mg), who showed a better performance than control subjects in tasks involving recall, visual memory, and spatial planning, and reported an increase in alertness, attention and energy (Turner et al., 2003). Again, a controlled study on healthy volunteers (n=16, aged 20-29 years), demonstrated that modafinil (200 mg), determined a significant decrease in error rates in the long delay condition of the visuo-spatial task and in the maintenance conditions, mainly in those with baseline performance subjects (Müller et al., 2004). Additionally, it has been reported that modafinil can increase self-confidence in subjects with sleep deprivation. As emerged in a sample of 41 healthy volunteers undergoing visual-perceptual judgement task and complex mental addiction task after sleep deprivation, modafinil significantly made subjects over-confident on their performance, notwithstanding a low performance accuracy (Baranski & Figueau, 1997).

The most frequent reasons reported for using modafinil concern boosting cognitive capacity, as well as being more performant. The results of an online survey carried out on 404 respondents of whom 219 were modafinil users (mostly male, American or British, university-educated, employed, with a mean age of 27), the most common motivation for misuse were “to increase attention”, “to work long hours”, “to get more done”, “exam”, “night work”, “to think more clearly”, and “other” (13%, n=28) (Teodorini et al., 2020).

**Dextroamphetamine**

Some data demonstrated that dextroamphetamine might improve cognitive ability in healthy adults. One of the first studies on adult population was carried out on a small sample of healthy college students (n=31, males aged 18-30). Participants, administered with different doses of dextroamphetamine (0.5 mg/kg, high dose group, or 0.25 mg/kg, low dose group), underwent different tasks to assess cognition, motor activity and mood. As far as cognitive abilities are concerned, high-dose subjects showed an increased vigilance and a significant improvement on cues recall and free recall. Even speech communication was increased, in particular the low-dose group showed a significant increase in alertness, attention and energy (Turner et al., 2003). Conversely, another double-blind, placebo-controlled trial on healthy volunteers (n=60) receiving atomoxetine (60 mg), no impact on probabilistic learning task emerged (Chamberlain et al., 2006). Additionally, another double-blind, randomized, placebo-controlled study on healthy subjects (n=12), showed that a single dose of atomoxetine (80mg) might increase neural sensitivity for errors, as well as to decrease the inhibitory control, during the Go/NoGo-Eriksen flanker paradigm (Graf et al., 2011).

**Prescribed nootropic drugs**

The term "nootrope", (from the ancient Greek words νόος “noos” mind and τροπeιν “tropoin” to turn) was first coined in 1972 to describe a novel psychotropic class able to increase cognitive skills initially in demented patients, with piracetam as the pioneer compound (Giurgea, 1973) soon followed by acetylcholinesterase inhibitors and memantine.

Nowadays there is an increasing use amongst the healthy population, as workers, soldiers and especially school and university students, in order to improve academic performance and to better manage stressful situations (Cakic, 2009; McDaniel et al., 2002). The prevalence of use is 16% and 35% amongst, respectively, European and USA students (Greely et al., 2008; Champagne et al., 2019) (table 3).

**Prescribed nootropic drugs**

The term "nootrope", (from the ancient Greek words νόος “noos” mind and τροπειν “tropin” to turn) was first coined in 1972 to describe a novel psychotropic class able to increase cognitive skills initially in demented patients, with piracetam as the pioneer compound (Giurgea, 1973) soon followed by acetylcholinesterase inhibitors and memantine.

Nowadays there is an increasing use amongst the healthy population, as workers, soldiers and especially school and university students, in order to improve academic performance and to better manage stressful situations (Cakic, 2009; McDaniel et al., 2002). The prevalence of use is 16% and 35% amongst, respectively, European and USA students (Greely et al., 2008; Champagne et al., 2019) (table 3).

**Piracetam**

Piracetam (pyrrolidone acetamide) has a chemical structure resembling that of GABA: this suggests that...
Table 3. Nootropics - Prevalence among college students and impact on cognition

| Authors and year | Type | N Participants | Drugs | Method | Results |
|------------------|------|----------------|-------|--------|---------|
| Maier et al., 2013 | Cross-sectional study | 6275 | Anti-dementia agents | Online survey | 0.1% of participants use anti-dementia drugs for neuroenhancement |
| Corazza et al., 2013 | Systematic review | - | Piracetam | Systematic literature review carried out in PsychInfo and Pubmed Database and additional sources of unstructured information from the Internet was carried out between February 2012 and July 2013 | Reason for use: Cognitive enhancement, Recreational use |
| De Oliveira Cata Preta et al., 2020 | Cross-sectional study | 1865 | Smart drugs | anonymous, self-administered questionnaire | Smart drugs use, 4.2% (within the last 12 months) methylphenidate 99.0% of users, Modafinil and piracetam account for 1% of use Of the respondents, 8.1% indicated that they had used cognitive enhancers. Among those who had used these drugs, nootropics were the most frequently mentioned (59.6%) |
| Lengvenyte et al., 2016 | Cross-sectional | 579 | Nootropics and other cognitive enhancers | Anonymous questionnaires consisting of 13 items | Memantine |

**Memantine**

| Authors and year | Type | N Participants | Drugs | Method | Results |
|------------------|------|----------------|-------|--------|---------|
| Schugens et al., 1997 | Double-blind placebo-controlled study | 16 | Memantine (30 mg) | Visual analogue mood rating scale, Benton test, Delay paradigm. | ↔ effects of memantine on mood, attention, immediate and delayed verbal and visuospatial memory |
| Rammsayer, 2001 | Double-blind, placebo-controlled, crossover design trial | 40 | Memantine (30 mg) | 20 objects and 20 photographs were presented on a computer screen. After a retention interval of 80 min, the participants' task was to select the original objects and faces from a set of 80 items. | ↓ Recognition performance for objects, ↑ performance on face recognition was not affected |
| Repantis et al., 2010 | Systematic review | - | Memantine | MEDLINE and EMBASE databases were searched (MEDLINE: 1950 to 2007/07-week 2, EMBASE: 1989 to 2007/07). | Not conclusive results about the impact of memantine on healthy subjects |
| Barnes et al., 1996 | Double-blind, placebo-controlled, crossover design trial | 24 | Memantine (30 mg/kg/day) | Electrophysiological and behavioural testing. | ↑ tendency to show more selective spatial search patterns |
| Zoladz et al., 2006 | Double blind, crossover design trial | 40 | Memantine and neramexane | Spatial memory task after intake of equimolar doses of memantine and neramexane. | ↑ long-term memory |
| Wise & Lichtman, 2007 | Preclinical study | 24 | Memantine, low doses (0.3 and 0.56 mg/kg) high doses (3 and 10 mg/kg) Donepezil Rimonabant | Radial-arm maze procedure | ↓ number of errors committed during the retrieval test (low doses), disrupted maze running (high dose) |
### Table 3. Acetylcholinesterase inhibitors

| Study                  | Design/Study Type                                      | Follow-Up | Treatment | Outcome Measures                                                                 |
|------------------------|--------------------------------------------------------|-----------|-----------|-----------------------------------------------------------------------------------|
| Yesavage et al., 2002  | Randomized, double-blind, parallel group, placebo-controlled trial | 18        | Donepezil (5 mg) for 30 days | Flight simulator ↑ ability to retain the capacity to perform a set of complex simulator tasks, ↑ retention of training on complex aviation tasks in nondemented older adults |
| Grön et al., 2005      | Randomized, double-blind parallel group placebo-controlled, repeated measures design trial | 30        | Donepezil (5 mg/day) for 30 days | Neuropsychological tests to assess cognitive status ↑ episodic memory in both the verbal and visual domain, and long-term visual episodic recall |
| FitzGerald et al., 2008| Double-blind crossover design trial                    | 20        | Donepezil (5 or 10 mg) for 6-week period | Levels of Processing task ↔ immediate and delayed recall of superficially processed, ↑ semantic processing and recall performance |
| Zaninotto et al., 2009 | Double-blind, placebo controlled, parallel group design study | 24        | Donepezil (5 mg) | The test battery included tasks that tap cognitive domains that are sensitive to acetylcholine manipulations |
| Repantis et al., 2010  | Systematic review                                       |            | Donepezil | MEDLINE and EMBASE databases were searched (MEDLINE: 1950 to 2007/07-week 2, EMBASE: 1989 to 2007/07). |
| LaBerge et al., 2018   | Double-blind, placebo-controlled, crossover study       | 121       | Galantamine (4 and 8 mg) | Mnemonic Induction of Lucid Dreams technique while returning to sleep. |
| Iglseder et al., 2018  | Narrative review                                         |            | Anti-dementia agents | Non systematic review of literature ↔ cognitive performance in healthy subjects |

### Table 3.Continued

| Study                  | Design/Study Type                                      | Follow-Up | Treatment | Outcome Measures                                                                 |
|------------------------|--------------------------------------------------------|-----------|-----------|-----------------------------------------------------------------------------------|
| Sannita et al., 1985   | Double-blind, placebo-controlled, balanced order design trial | 18        | Piracetam (doses 800-4,800 mg) | EEG, Modified Abramson symptom questionnaire ↓ low-frequency components, ↑ power of the 8.5- to 12.0-Hz and of the fast-frequency components of EEG (anterior scalp areas) |
| Grossman et al., 2011  | Preclinical study                                     | 336       | Piracetam (mild dose 25-400mg/L, high dose 700 mg/L) | Novel tank and light–dark anxiety tests, Plus-maze test, The zebrafish novel tank test ↔ fish novel tank and light–dark box behavior at mild doses, and inhibition at high dose, ↔ inter-/intra-session habituation in the novel tank test for acute or chronic mild dose ↑ cued learning plus-maze test |
it probably acts as a GABA mimetic drug (Wischer et al., 2001). However, it has been proposed that its main pharmacological activity would consist in the activation of the glutamate α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, and as such, to increase their density and calcium uptake, possibly resulting in elevation of intracellular calcium levels (Ahmed & Oswald, 2010; Copani et al., 1992). As a result, piracetam would exert a neuroprotective action through improvement of brain membrane fluidity and neuroplasticity (Brandão et al., 1995).

Piracetam was and is still used to treat neurological disorders, such as early stages of Alzheimer’s disease and memory impairment due to age (Waegemans et al., 2002). Possible cognitive enhancement and memory improvement are some of the reasons for its use amongst healthy subjects (Corazza et al., 2013). However, studies demonstrating that piracetam may effectively improve wakefulness and memory, were mainly conducted on animal models (Grossman et al., 2011; Samartgis et al., 2012), while information on healthy individuals is limited (Alkuraishy et al., 2014; Sannita et al., 1985). The first observations in healthy adults were carried out since the ’70s. Amongst those, a double-blind, placebo-controlled, cross-over design study on a sample of normal elderly individuals (n=29), reported that piracetam exerted a significant effect on different cognitive tasks. Participants received a placebo for a week, then were divided in two halves, with one half receiving piracetam for a four-week period, while the other half placebo. After crossing-over, those subjects starting with piracetam received placebo and vice-versa. In general, when taking piracetam, individuals obtained better results in some different cognitive tasks (Mindus et al., 1976). The improving effect of piracetam (800 mg/die for four days) on memory and cognitive skills was supported by a more recent study conducted on healthy male volunteers (n=30). In particular, the drug exerted a significant effect on cognitive and working memory at all levels of computerized n-Back test (p <0.05), although its impact on psychometric reaction time parameters was negligible, with the single exception of the total reaction time which resulted boosted (Alkuraishy et al., 2014).

Although the impact of piracetam on cognitive ability is limited, it has become popular among college students. A cross-sectional survey study performed on students of two Lithuanian universities (n=579, response rate 95%) highlighted that 8% of the respondents had used nootropics, especially piracetam (59.6%) (Lengvenyte et al., 2016). However, as reported by a similar study on Brazilian college students (n=1865), piracetam accounted only for 1% of use (de Oliveira Cata Preta et al., 2020).

### Acetylcholinesterase inhibitors

Acetylcholinesterase inhibitors (AChEIs) (donepezil, galantamine and rivastigmine) that improve cholinergic transmission by reducing ACh degradation, are commonly used in the treatment of both Alzheimer’s and Parkinson’s disease (Birks, 2006; Emre et al., 2004; Kandiah et al., 2017; McShane et al., 2006; Racchi et al., 2004; Rogan & Lippa, 2002; Sonkusare et al., 2005). Donepezil and galantamine are pure AChE inhibitors, while rivastigmine inhibits both AChE and butrycholinesterase (Weinstock, 1999). A few trials reported positive effects of these drugs on cognitive impairment of schizophrenia and drug abuse patients (Kishi et al., 2018; Ribeiz et al., 2010). Limited evidence would also indicate some efficacy of AChEIs to improve cognitive ability in healthy subjects. In a study, donepezil showed beneficial effects on maintaining complex aeronautical skills in retired healthy pilots (Yesavage et al., 2002). Again, this drug has been reported to improve both episodic and semantic memory (FitzGerald et al., 2008; Grön et al., 2005) and mood in healthy individuals (Zaninotto et al., 2009). Donepezil and galantamine were also shown to stimulate the lucid dreaming (LaBerge, 2000; LaBerge et al., 2018). Lucid dreaming is that particular state in which an individual is aware of the fact that he is dreaming, while actually being asleep (REM sleep phase). This is a phenomenon that some individuals find pleasurable, and it has been related to the ability of ACh and AChEIs to regulate REM sleep and to increase the number of REM sleep phases. Amongst students, AChEIs do not seem to be appreciated as neuroenhancers, since only 0.1% reported to use them (Maier et al., 2013), or not to use them at all (Schelle et al., 2015). In any case, according to a recent review,
Neuroenhancement: state of the art and future perspectives

Clinical Neuropsychiatry (2021) 18, 3

approximately 65% of college students used alcohol. From these studies emerged that, in a given month, active, that collected data from 15,000 college students. College Alcohol Study (CAS), although no longer Related Conditions (NESARC), and by The Harvard the National Epidemiologic Survey on Alcohol and Alcoholism (NIAAA), by surveying 46,500 adults with ongoing trends in college drinking. Other relevant data are questioned in subsequent years, in order to monitor that every year approximately 2,400 graduating seniors face interviews (67,500 individuals, aged 12 and older), sponsored by the Substance Abuse and Mental Health drinking habits of college students, the National Survey images more enjoyable (Dolder et al., 2017).

Alcohol

The anxiolytic action of alcohol is one of the main reasons for its wide use and abuse. Generally, alcohol is taken to reduce anxiety caused by social interactions, but it is well known that at high concentrations and/ or chronic use it may impair attention, provoke ataxia, slow reactions and amnesia. When blood levels are >300 mg/dl, potentially fatal respiratory depression can occur (Nutt, 1999). Alcohol has an inhibitory GABAergic effect that, together with the inhibition of excitatory glutamatergic receptors, may provoke a taken-reducing activity on the CNS. Alcohol shows an excitatory effect at the level of mu-opioid receptors involved in the reward system, and interacts with the serotonergic processes related to well-being and mood elevation (Costardi et al., 2015).

Alcohol can increase sensitivity to expressions of disgust and contempt (Felisberti & Terry, 2015), as well as facilitate the recognition of happy faces and increase emotional empathy ratings for positive stimuli (Dolder et al., 2017). Interestingly, although it does not increase sexual arousal, it was found to make pornographic images more enjoyable (Dolder et al., 2017).

In USA, several national survey studies investigating drinking habits of college students, the National Survey on Drug Use and Health (NSDUH), the annual survey sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA), based on face-to-face interviews (67,500 individuals, aged 12 and older), that every year approximately 2,400 graduating seniors are questioned in subsequent years, in order to monitor ongoing trends in college drinking. Other relevant data derive from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), by surveying 46,500 adults with the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), and by The Harvard College Alcohol Study (CAS), although no longer active, that collected data from 15,000 college students. From these studies emerged that, in a given month, approximately 65% of college students used alcohol. However, although from the ‘90s the total number of alcohol drinkers decreased, the total amount of frequent binge-drinkers increased (three or more binge-drinking episodes in a 2-week period). With regard to gender differences, although alcohol use was more frequent among males some decades ago, nowadays there is no difference, as reported in every country (White & Hingson, 2013).

It is estimated that more than 90% of college students consume alcohol for recreational use, given its easy availability and low costs. However, approximately 5% of academic students admit using alcohol even as a neuroenhancer, especially during the last month before an exam (Maier et al., 2013). Different reasons have been reported to explain the high prevalence of this phenomenon. Acute stress situations were found to increase selectively voluntary alcohol intake in undergraduate university students (Magrys & Olimstead, 2015). In addition, emotion dysregulation seems to play a critical role in alcohol-related problems of women attending college (Messman-Moore et al., 2010). A study carried out in a large sample of students (n=33,813) from 13 European countries, reported a social motivation, which was the most common reason for drinking, followed in this order by enhancement, coping and conformity motives in all countries involved except Finland (Kuntsche et al., 2014). The use of alcohol as a social enhancer is well described in an Australian study investigating the consumption of alcohol during “Schoolies”, the immediate post-school celebration period lasting about four days. An online survey was administered to students in their senior year of school and participants anticipated that they would consume eight standard drinks a day and planned to spend substantial amounts of money on alcohol during Schoolies, demonstrating the importance of reducing the salience of alcohol in the course of this period (Jongenelis et al., 2017). Similarly, another research carried out through online questionnaires targeting 18-29 aged Irish university students showed that 81.6% of respondents were alcohol users and 44% of them declared an increase in consumption as they started university. A large part of them (66.4%) reported “to be sociable” as the primary reason for alcohol consumption, followed “enjoyment” (10.7%) and “relax” (6.4%) (Muli & Lagan, 2017). However, alcohol is used also to reduce anxiety due to academic performance, as confirmed by different studies. A Bosnian-Herzegovinian investigation on 214 students found that almost a quarter of participants increased their consumption of alcohol during the last week before exams, with no correlation with anxiety symptoms (Kusturica et al., 2019). Furthermore, burn-out syndrome can be considered another risk factor for alcohol abuse or addiction, as reported in a sample of American medical students, who met the diagnostic criteria for such a condition in one third of cases, as educational debt further may increase the risk (Jackson et al., 2016). A dangerous and harmful use seems more likely in the male sex, while the most common reason related to alcohol use has been the social enhancement (Oliver et al., 2014).

To sum up, alcohol use among college students is widespread and often excessive. A significant number of them tend to use alcohol not only for recreational reasons, but also as a neuroenhancer, mostly to cope with anxiety during exams or stressful conditions that are frequent in academic life. However, students do not seem totally aware of the biological risks of drinking excessive quantities of alcohol and they tend to have too high expectations on its alleged impact on

ACKNOWLEDGMENTS

Clinical Neuropsychiatry (2021) 18, 3 147
cognition. All these motivations, coupled with the easy availability of alcoholic beverages is at the basis of the increased alcohol consumption worldwide amongst adolescents and students who are not aware of the long-term consequences on cognitive functions that may indeed result dramatically impaired (Brennan et al., 2020). In addition, the heavy alcohol use amongst university students requires the implementation of specific information about the risks of alcohol abuse, and appropriate prevention/intervention programs (table 4).

Illicit drugs

Illegal drugs, such as hallucinogens (mescaline, lysergic acid diethylamide, psilocybin), non-prescribed stimulants, ecstasy, or other designer drugs, are widely used by healthy individuals as emotional enhancers (Normann & Berger, 2008) (table 5).

Hallucinogens

Hallucinogens were defined as “psychedelic” substances by the psychiatrist Humphrey Osmond in 1957, since they were thought to have a mind-revealing capability (from the Ancient Greek words ψυχή, “soul” and δηλοῦν, “to make visible, to reveal”) (Osmond, 1957), although they cause permanent hallucinatory symptoms.

Mescaline

Mescaline is a natural psychedelic alkaloid present

| Table 4. Alcohol - Prevalence among college students, reasons for use and impact on cognition |
| Authors and year | Type | N | Methods | Results |
| Maier et al., 2013 | Cross-sectional | 6275 | Questionnaire specifically designed at the Swiss Research Institute for Public Health and Addiction | Alcohol use, 90% Social reasons were the most common Use alcohol for neuroenhancement, 5% |
| White et al., 2013 | Narrative review | 50000 | National Survey on Drug Use and Health (NSDUH), the annual survey sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA) National Institute on Alcohol Abuse and Alcoholism (NIAAA) National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), The Harvard College Alcohol Study (CAS) | Approximately 65% of college students used alcohol. Although from the ’90s the total number of alcohol drinkers decreased, the total amount of frequent binge-drinkers increased |
| Kuntsche et al., 2014 | Cross-sectional | 33813 | Drinking Motives Questionnaire Revised Short Form (DMQ-R SF) | The most common reasons for drinking were social motivation, enhancement, coping, and conformity |
| Messman-More et al., 2014 | Cross-sectional | 424 | The Difficulties in Emotion Regulation Scale (DERS), Drinking Motives Questionnaire–Revised (DMQ-R), Alcohol Use Disorders Identification Test (AUDIT) | Emotion dysregulation predicted drinking coping motives |
| Oliver et al., 2014 | Cross-sectional | 349 | Self-administered paper survey | Reasons for use: social motives were the most common. Coping and enhancement motives were more predictive of harmful or hazardous alcohol use (23.2% of students) ↑ sensitivity to expressions of disgust and contempt (not depending on stimulus duration) |
| Felisberti et al., 2015 | Placebo-controlled, repeated-measures design | 18 | Simula representing six emotions were used Alcohol high dose 0.6 g/kg for male, 0.52 g/kg for female, low dose, 0.2 g/kg for male and 0.17 g/kg for female | ↑ sensitivity to expressions of disgust and contempt (not depending on stimulus duration) |
| Magrys et al., 2015 | Randomized, placebo controlled trial | 75 | Trier Social Stress Test or no-stress protocol, 30-min free-drinking session (alcohol, placebo, or non-alcoholic beverage). The State-Trait Anxiety Inventory | Psychosocial stress ↑ voluntary intake of alcohol, but not placebo or non-alcoholic beverages |
| Jackson et al., 2016 | Cross-sectional | 4402 | National survey | Burn out, depression, low mental or emotional QOL ↑ risk for alcohol abuse/dependence |
Neuroenhancement: state of the art and future perspectives

Dolder et al., 2017
Double-blind, random-order, crossover design trial
60
Face emotion recognition task (FERT), Multifaceted Empathy Test (MET), and Sexual Arousal Task (SAT), Visual analog scales (VASs).
↑ VAS ratings of stimulated, happy, talkative, open, and want to be with others. ↑ recognition of happy faces on the FERT, ↑ emotional empathy for positive stimuli on the MET.

Jongenelis et al., 2017
Cross-sectional
187
Ad hoc survey
Students referred planning to consume 8 standard drinks a day.

Muli et al., 2017
Cross-sectional
595
Online questionnaire
Alcohol users, 81.6%, ↑ consumption of alcohol after starting university, 44%. Reasons for use: “to be sociable”, 66.4%, “enjoyment”, 10.7%, and relax 6.4%.

Kusturica et al., 2019
Cross-sectional
214
Ad hoc questionnaire
West-side test anxiety scale (WTAS)
↑ consumption of alcohol during the last week before exams, with no correlation with anxiety symptoms.

Brennan et al., 2020
Systematic review
- Search MEDLINE, Embase and PsycINFO (January 2007 to April 2018)
27 cohort study included
↑ cognition among women with moderate alcohol consumption compared to current non-drinkers, ↔ for men. However, low level evidences.

Table 5. Illicit drugs - Prevalence among college students, reasons for use and impact on cognition

| Authors and year | Type | N | Method | Results |
|-----------------|------|---|--------|---------|
| micro-doses of psychedelics |
| Lea et al., 2020 | Cross-sectional | 1102 | Online survey | Alternative treatment for mental health (40%), personal development and well-being (31%) and improvement of cognitive functions (18%) |
| Lea et al., 2019 | Subreddit analysis | 714 | Online discussion forums | The third common motivation is to enhance cognitive performance |
| Hutten and al., 2019 | Cross-sectional | 1116 | Online survey | LSD and psilocybin (the most used), improve performance (main motivation) |
| MDMA |
| Maier, 2013 | Cross-sectional | 6275 | Online survey | 0.1% of academic students only use MDMA for neuroenhancement |
| Stimulants |
| Teter et al., 2006 | Cross-sectional | 4580 | Online survey | The most used stimulant in the past year was Adderall. Non-prescribed stimulants use was significantly more prevalent among Caucasian and Hispanic students. The more frequent reasons were to improve concentration, help study and increase alertness as well as recreational reasons including getting high and experimentation. Some sex differences were reported, with men using more NPS “to experiment”, and women to lose weight |
| De Santis et al., 2008 | Cross-sectional | 1811 | Quantitative surveys and qualitative interviews | 34% had used NPS and 63% of these had never taken NPS before college. The most common reasons were “stay awake to study” and “improve concentration”. The vast majority of NPS users get them from friends. On the whole, although students reported to use stimulants to face academic stress, they showed to not be adequately informed on the possible risk of using stimulants as neuroenhancers, but they consider the potential side effects acceptable |
| Weyandt et al., 2009 | Cross-sectional | 363 | Brief Symptom Inventory, The Internal Restlessness Scale, the Sensation Seeking Scale, the Stimulant Survey Questionnaire | NPS users (7.5%). Different correlations emerged between the use of NPS and rates of psychological distress, internal restlessness, and sensation-seeking behaviour |
Hall et al., 2005  Cross-sectional  381  85-item questionnaire designed by the investigators on the basis of the survey prepared by Moline and Frankenberger  Only 14% of NPS users believe that stimulants may improve their academic performance in the long term

Arria et al., 2008  Cross-sectional  1253  2-hour personal interview  Approximately 18% used stimulants for non-medical reasons. 33.3% of ADHD students referred to have overtaken their own stimulants or to have used someone else’s stimulants for non-medical reasons at least once in their lifetime. Amphetamine and dextroamphetamine were used by the vast majority of NPS users

| Cannabinoid compounds | Eickenhorst et al., 2012 | Cross-sectional | 1218 students | Web-based survey | Higher prevalence of cannabis use for neuroenhancement (14%), especially amongst men
| | Kusturica, 2019 | Cross-sectional | 214 students | Westside Test Anxiety Scale and academic performance | Cannabis use tends to increase during the week before exams in 19% of students
| | Schelle et al., 2015 | Cross-sectional | 1572 | Online survey | 1.3% of them used cannabinoids with the purpose of neuroenhancement
| | Bonar et al., 2017 | Longitudinal study | 95 | Online survey | Significant correlations between the amount of cannabis used and the reason for its use, including social enhancement and/or coping
| | Bravo et al., 2017 | Cross-sectional | 2129 | Online survey | Positive association between marijuana use frequencies and coping strategies, expansion motives, and enhancement
| | Glodosky et al., 2020 | Cross-sectional | 988 | Online survey | Cannabis is frequently used against stress, depression, and anxiety, coping motives may be related to higher levels of depression, while expansion and conformity reasons to higher levels of anxiety
| | Bae et al., 2019 | Cross-sectional | 234710 | Self-reported marijuana use | After recreational marijuana legalization (RML) policy cannabis use has increased among students in term of past month prevalence in RML and non RML exposed
| | Olla et al., 2019 | Observational study | 22 | Brief neurocognitive battery | Participants’ cognitive performance remained stable or even improved during the acute intoxication phase

Table 5. Continued

| Authors and year | Type | N | Illicit | Method | Results |
|---|---|---|---|---|---|
| Mescaline | Halpern et al., 2005 | Clinical trial | 120 | Mescaline | Screening interview, the Rand Mental Health Inventory (RMHI), neuropsychological tests of memory and attentional/executive functions | No evidence of psychological or cognitive deficits among Native Americans using peyote regularly
| | Papaseit et al., 2018 | Observational study | 16 | Synthetic compounds showing mescaline-like | Visual analog scale (VAS), the Addiction Research Centre Inventory (ARCI), and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE), The Hallucinogenic Rating Scale | Changes in VAS, ARCI, ↑ VESSPA-SSE

| Lysergic acid diethylamide (LSD) | Kaelen et al., 2015 | Randomized, one-blind, placebo controlled trial | 10 | LSD 40, 50, 70, or 80 μg, placebo | Visual analogue scale (VAS) and the Geneva Emotional Music Scale (GEMS-9) | ↑ emotional response to music
Table 5. Continued

| Study | Design | Participants | Treatment | Outcome Measures | Key Findings |
|-------|--------|--------------|-----------|------------------|--------------|
| Liechti et al., 2017 | Placebo-controlled, double-blind, cross-over design | 40 | 100 and 200 μg LSD | 5 Dimensions of Altered States of Consciousness (5D-ASC), Mystical Experience Questionnaire (MEQ) | ↑ mystical experience, changes in meaning of percepts, ↑ insightfulness |
| Pokorny et al., 2019 | Double-blind, randomized, placebo-controlled study | 25 | LSD (100 μg) ketanserin (40 mg) placebo | Intra/Extra-Dimensional shift task (IED), Spatial Working Memory task (SWM), and Cambridge Gambling Task (CGT) of the Cambridge Neuropsychological Test Automated Battery. | ↓ executive functions, cognitive flexibility and spatial working memory |
| Hasler et al., 2004 | Double-Blind, Placebo-Controlled Dose-Effect Study | 8 | Psilocybin 45, 155, 315 microg/kg body weight PY, placebo | Altered States of Consciousness Rating Scale (5D-ASC), the Frankfurt Attention Inventory (FAIR), the Adjective Mood Rating Scale (AMRS) | ↑ alterations in the self, perception, affection and attention |
| Pokorny et al., 2017 | Double-blind randomized, placebo-controlled trial | 32 | Psilocybin 0.215 mg/kg p.o., placebo | Multifaceted Empathy Test (MET), the Moral Dilemma Task (MDT), The Altered States of Consciousness Rating Scale (5D-ASC), The Positive and Negative Affect Schedule (PANAS) | ↑ emotional empathy associated with the change in meaning of perceptions. ↔ moral behavior |
| Carter et al., 2005 | Double-blind, placebo-controlled study | 8 | Psilocybin 215 microg/kg, ketanserin 50mg, placebo | Attention—Multiple-object Tracking, Cambridge Neuropsychological Test Automated Battery (CANTAB), Spatial Span test, The Altered State of Consciousness (5D-ASC) rating scale | ↓ attentional tracking ability, ↔ spatial working memory. |
| Anderson et al., 2019 | Observational study | 909 | Microdoses (ng) of psychedelics | Online survey | ↓ dysfunctional attitudes and negative emotionality, ↑ wisdom, creativity and open-mindedness |
| Hysek et al., 2013 | Double-blind, placebo-controlled study | 32 | Single dose of MDMA (125 mg) | Multifaceted Empathy Test (MET), dynamic Face Emotion Recognition Task (FERT) and Social Value Orientation (SVO) test | ↑ empathy at MET, and pro-social behavior, at the SVO test in men. ↔ cognitive empathy in the MET, ↓ identification of negative emotions in the FERT, particularly in women |
| Kuypers et al., 2017 | Placebo-controlled study | 118 | MDMA (single dose, 75 or 125 mg) | Multifaceted Empathy Test (MET) | ↑ emotional empathy for positive emotions at MET |
| Kirkpatrick et al., 2015 | Randomized controlled trial | Study 1: 361 Study 2: 32 | MDMA | Welfare Trade-Off Task (WTT) | ↑ generosity towards others |
| Becker et al., 2014 | Longitudinal study | 70 | Marijuana | Neurocognitive battery | ↑ processing speeds than control subjects, ↑ cognitive deficits (verbal memory, spatial working memory, spatial planning and motivated decision-making) |
| LaFrance et al., 2017 | Cross-sectional study | 721 | Cannabis | Neuroticism, Extraversion, Openness to Experience Five Factor Inventory, Daily Sessions, Frequency, Age of Onset, and Quantity of Cannabis Use Inventory, Kaufman Domains of Creativity Survey, Creative Behaviors Inventory, Alternate Uses Test modified from the Uses of Objects Test, Remote Associates Test | Sober users ↑ creative and convergent thinking. |
in high concentrations in the North American peyote cactus (El-Seedi et al., 2005), acting as a partial agonist at the level of the 5-HT2a receptors (Nichols, 2004). After its administration, it induces important thinking alterations, distortions of the onself’s sense of time and reality perception, as well as an increase in suggestibility and a greater intensity of emotions (Grinspoon & Bakalar, 1997). To the best of our knowledge there are no clinical trials on healthy individuals on mescaline as neuroenhancer, with a single exception of a study conducted on Native Americans, who regularly ingest peyote for religious reasons, that did not highlight any psychological benefits or detrimental consequences (Halpern et al., 2005). However there are some studies on synthetic compounds with a mescaline-like structure, including as 2,5-dimethoxy-4-ethylphenethylamine (2C-E) and 2,5-dimethoxy-4-bromophenethylamine (2C-B), which have become popular as new psychoactive substance over the last decades. An observational study on a small sample of 2C-compound users (n=16, 8 female subjects) found that 2C-B determined statistical significant changes in almost all domains of the Visual Analogue Scale, particularly hallucinations (seeing animals, things, insects, or people or hearings of sounds or voices) (Papaseit et al., 2018). Also, significant changes in Addiction Research Center Inventory (ARCI) questionnaire emerged in those subscales measuring euphoria or dysphoria, somatic symptoms, intellectual efficiency and energy subscales (modest). Similarly, an increase in the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) questionnaire emerged in pleasure and sociability, activity and energy, and sedation subscales (Papaseit et al., 2018). Particularly, a non-controlled, prospective, observational study on recreational drug users who had experienced 2C compounds at least once, reported that 2C-E induce significant changes in perceptions, as detected by Visual Analogue Scales (VAS) including “changes in colors”, “changes in lights”, “different body feeling”, and “different surroundings” after four hours from substance consumption (Papaseit et al., 2020). In any case, there is no controlled study to assess the potential of mescaline as neuroenhancers in healthy subjects.

Lysergic acid diethylamide (LSD)

Lysergic acid diethylamide (LSD) is a unique molecule synthesized for the first time by the Swiss chemist Dr. Hoffman with the aim of studying the possible therapeutic uses of ergot derivatives (Hwang & Saadabadi, 2020). LSD potently binds to 5-HT1A, 5-HT2A, 5-HT2C, dopamine D2, and α2 adrenergic receptors and less potently to α1 adrenergic, D1, and D3 receptors (Rickli et al., 2015). Different studies reported that LSD impacts on sensorial perception by inducing a blissful state, synesthesia, derealization and depersonalization and increasing insightfulness. Similarly, it may boost emotional empathy, as well as to facilitate interpersonal relations (Carhart-Harris et al., 2016, Liechti, 2017). Furthermore, a study showed that subjects who had taken LSD before listening to music had increased emotional response to music compared to those who had taken placebo (Kaelen et al., 2015). Two placebo-controlled, double-blind, crossover studies conducted on two small sample of subjects administered with LSD (100 and 200 μg, respectively) reported that this drug might induce mystical experience, although they were not frequent, and changes in meaning of percepts, increase insightfulness and induce a blissful state, as measured by the 5 Dimensions of Altered States of Consciousness (5D-ASC) scale. All these effects were dose-dependent (Liechti, 2017). With regard to cognitive effect of LSD, a study on healthy subjects taking LSD, placebo or LSD + ketanserin, a 5-HT2A antagonist, showed how LSD significantly compromised executive functions, cognitive flexibility and spatial working memory, with no influence on the quality of decision-making and risk taking, while ketanserin normalized all cognitive deficits (Pokorny et al., 2017). However there are no specific studies investigating LSD’s role as neuroenhancer.

Psilocybin

Psilocybin is an alkaloid present in 200 of the so-called “magic mushrooms”, as these are commonly called (Musshoff et al., 2000). From the pharmacological point of view, it binds with high affinity at 5-HT2A and with less affinity at 5-HT1A, 5-HT1D and 5-HT2C (McKenna et al., 1990). A study exploring its effects versus placebo concluded that all subjects who had taken the active compound reported important alterations in the self, perception, affection and attention (Hasler et al., 2004). During intoxications, emotions can vary from pleasant and ecstatic to anxiety (Vollenweider et al., 1997). Another study noted that psilocybin significantly increases emotional empathy associated with the change in meaning of perceptions. By contrast, it did not seem to impair moral behavior (Pokorny et al., 2017). To evaluate the impact of psilocybin on healthy subjects, a sample of volunteers were recruited and evaluated after administration of psilocybin, placebo, ketanserin or psilocybin + placebo. Those who had taken psilocybin showed a significant reduction in attention tracking ability, but no effect on spatial working memory. Pre-treatment with ketanserin did not reduce the attention tracking ability deficit. The results suggest that there is a functional dissociation between the two tasks and that perhaps 5-HT1A receptors are primarily involved in the observed deficit (Carter et al., 2005).

However, in recent years there has been a widespread interest in micro-doses of psychedelics to improve mental health, wellbeing and increase cognitive performance. An international study was conducted on an online sample of microdosing users, mainly of psilocybin and LSD. Its results showed that the main motivation for this practice was an alternative treatment for mental disorders (40%), followed by personal development and wellbeing (31%) and improvement of cognitive functions (18%) (Lea et al., 2020). An analysis conducted on discussion about microdosing of psychedelic compounds from an online forum showed that the third common motivation is to enhance cognitive performance in work and school, with the aim of improving concentration, productivity, creativity and problem solving (Lea et al., 2020). Another online questionnaire revealed that the most frequently used psychedelics were LSD and psilocybin and the main motivation was to increase performance. Interestingly, most users were not aware of the dose they were using (Kluten et al., 2019). Further, the results of an observational study showed that current and past microdosing users had lower scores on measures of dysfunctional attitudes and negative emotionality, and higher scores on wisdom, creativity and openness-mindedness, than a control group (Anderson et al., 2019).
Amphetamines and non-prescribed stimulants

Amphetamines, and in particular the subtypes defined as "entactogen", including the 3,4-methylenedioxy-N-methylamphetamine (MDMA, ecstasy), enhance empathy and social interactions, increase a sense of attachment towards the self and the others, as well as reduce social anxiety (Carlyle et al., 2019; Hysek et al., 2014; Nichols, 1986; Normann & Berger, 2008), although they are potent inducers of severe, treatment-resistant depressive episodes and psychoses (Glasner-Edwards & Mooney, 2014).

A double-blind, placebo-controlled study on healthy subjects (n=32, 16 women) taking a single dose of MDMA (125 mg) found that this drug increased empathy, as assessed by the Multifaceted Empathy Test (MET), in both sexes, and pro-social behavior, as measured by the Social Value Orientation (SVO) test in men only. Furthermore, MDMA did not affect cognitive empathy of the MET, and reduced the identification of negative emotions in the Face Emotion Recognition Test (FERT), particularly in women (Hysek et al., 2014). These results were subsequently confirmed by another placebo-controlled study on 118 healthy volunteers (with the only difference that MDMA doses were 75 or 125 mg). Similarly, MDMA administration determined an increase in emotional empathy for positive emotionally charged situations of the MET, while this effect was low for negative emotions (Kuypers et al., 2017). In line with the previous study, cognitive empathy resulted unchanged, while generosity towards others resulted increased (KirKPATRICK et al., 2015).

Stimulants are widely used among university students worldwide as neuroenhancers. As reported by a Swiss research on a large sample, it is estimated that 0.1% of academic students use MDMA for neuroenhancement (Maier et al., 2013). In studies carried out in the USA, its lifetime use resulted higher than that recorded in Switzerland. One of the largest American studies was conducted on a sample of 4580 college students. Participants, who were assessed by an online survey, reported a lifetime history of non-prescribed stimulants (NPS) use of 8.3% and of 5.9 % in the last year. In this case, the amphetamine-dextroamphetamine combination Adderall was the most used stimulant. The NPS use was significantly more prevalent among Caucasian and Hispanic students, who were three times more likely to consume stimulants, as compared with African-Americans and Asians. Different reasons were reported for using NPS, although the most frequent were the following: to improve concentration, to help study and to increase alertness, or recreational reasons including getting high (31.0%) and curiosity (29.9%). Furthermore, some sex differences were reported, with men using more NPS "to experiment", and women to lose weight (Teter et al., 2006). A study conducted on undergraduates (n=1,811) from a southeastern USA university reported that 34% had used NPS, and 63% (n=368) of these had never taken NPS before going to the college. The most common reasons were "stay awake to study" and "improve concentration", followed by "help memorize" and "stay awake to have fun". Less frequent reasons include "feel high", "reduce appetite" and "Attention-deficit hyperactivity disorder (ADHD) self-medication". The vast majority of NPS users (87%) get them from friends, while only 4% of the overall sample from physicians for their ADHD. On the whole, although students reported to use stimulants to face academic stress, they showed to be poorly informed on their possible risk as neuroenhancers, as other students represent the main source of information.

In any case, they consider the potential side effects of NPS acceptable, while overestimating their possible advantages (DeSantis et al., 2008). Lower percentages of NPS users (7.5%) were found in another study conducted in a northeast USA university on a smaller sample of college students (n=363). Different correlations emerged between the use of NPS and rates of psychological distress, internal restlessness, and sensation-seeking behaviour, measured by different rating scales (Weyandt et al., 2009). Similar results were reported in a study conducted in a university of the Midwest, where only 14% of NPS users believed that stimulants may improve their academic performance in the long term (Hall et al., 2005).

In Spain, a study on 1253 first-year university students, demonstrated that approximately 18% of them was using stimulants for non-medical reasons. Furthermore, 33.3% of ADHD students referred to have overtaken their own stimulants, or to have used someone else's stimulants for non-medical reasons at least once in their lifetime. Stimulant-prescribed females turned out to be more prone to non-medical use of stimulants, compared with their male counterpart (37.5% vs 20.7%). Amphetamine and dextroamphetamine were the most used NPS (89.3%), followed by MPH, and MPH extended-release (Arria et al., 2008).

In conclusion, the abuse of NPS is an increasing phenomenon especially in highly competitive academic settings that should be not only carefully monitored, but also prevented through appropriate information campaigns.

Cannabinoid compounds

The United States Code (USC) indicates with the term “marihuana/cannabis” “all parts of the plant cannabis sativa L., whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin”. Psychotropic and behavioral effects are due to the plant’s cannabinoid content, with Δ9 -tetrahydrocannabinol (Δ9-THC), mainly found in leaves and flower buds, being the most active (ElSohly et al., 2017). The action of Δ9-THC is mediated by two major G-protein coupled receptors, cannabinoid receptor type 1 (CB1) and CB2, expressed within and outside the brain (Pertwee, 2014). Cannabis also contains psychotomimetic phytocannabinoids that seems to exert positive effects on several neuropsychiatric disorders and neurodegenerative diseases (Campos et al., 2016).

Given the wide consumption of cannabinoids worldwide, it is not surprising that they are also used as neuroenhancers, although at a lower rate than NPS. A German study on students (n=1,218) reported higher prevalence of cannabis use for neuroenhancement (14%), especially amongst men (Eickenhorst et al., 2012). Furthermore, it has been reported that cannabis use tends to increase during the week before exams in 19% of students (Kusturica et al., 2019). A Dutch study on university students (n=1,572) revealed that 1.3% of them used cannabinoids with the specific purpose of neuroenhancement (Schelle et al., 2015). A study on patients aged 18-25 years (n=95) recruited from an urban Emergency Department, found significant correlations between the amount of cannabis used and the reason for its use, including social enhancement and/or coping (Bonar et al., 2017). Similar results were reported in a study on a large sample (n=2,129) of college students of 11 different USA universities, reporting a positive association between marijuana use frequencies and...
coping strategies, expansion motives, and enhancement (Bravo et al., 2017). In line with these findings, an analysis of a sample of 988 college students who were cannabis users, highlighted a moderator role of coping for the relationship between stress and depression, while expansion and conformity would play a significant role in the relationship between stress and anxiety. In other words, although cannabis is frequently used against stress, depression, and anxiety, coping reasons may be related to higher levels of depression, while expansion and conformity reasons to higher levels of anxiety (Globosky & Cuttler, 2020). These results should be evaluated carefully, considering that, after recreational marijuana legalization (RML) policy in some American states, cannabis use has increased significantly amongst students in term of past month prevalence in RML and non RML exposed (Baë & Kerr, 2020).

With regard to the impact of cannabis on cognition, results are still controversial. On the one hand, a study considering 22 individuals with prescription marijuana from southwestern Ontario who were given a cognitive battery to assess cognitive performance, assuming they were adversely affected by acute intoxication, found that participants’ cognitive performance remained stable or even improved during the acute intoxication phase (Olla et al., 2019). On the other hand, a controlled study was conducted on subjects aged between 18 and 20, of whom 35 were daily marijuana users who started using the drug before the age of 17, and 35 were healthy non-user control subjects. All subjects were assessed by a comprehensive neuropsychological battery. The results suggested that users showed relatively higher processing speeds than control subjects, but they had different cognitive deficits, especially in verbal memory, spatial working memory, spatial planning and motivated decision-making (Becker et al., 2014).

Another study was conducted to explore the possibility that cannabis might increase creativity, as suggested by previous research. However, the results showed that sober users were more creative and had better results with regard to convergent thinking, although these effects seem to be mainly related to the higher levels of expectation and openness to experience of cannabis users (LaFrance & Cutler, 2017).

To summarize, on the basis of available data, cannabinoid compounds seem to exert no neuroenhancing effects.

**Soft enhancers**

The term “soft enhancer” refers to non-prescription drugs, food supplements, caffeine-containing products, herbal derivative, such as ginkgo biloba, that are used as neuroenhancers, especially by students (Dietz et al., 2018; Micoulaud-Franchi et al., 2014) (table 6).

**Caffeine**

Caffeine (1,3,7-trimethylxanthine) is the stimulant most used by man, especially as a component of tea, coffee, cola and energetic drinks (Nehlig, 2010). The main mechanisms of action of caffeine consist in the intracellular mobilization of calcium as ryanodine receptor agonist, inhibition of phosphodiesterases and antagonism of all types of adenosine receptors (AR): A1, A2A, A3 and A2B. However, at average levels of caffeine consumption (~210-238 mg/d), caffeine’s main mechanism of action is antagonism of adenosine receptors (Dobson et al., 2015; Nehlig, 2010), thereby removing the endogenous adenosinergic tone, and affecting brain functions such as sleep, cognition, learning and memory (Ribeiro & Sebastião, 2010). In the medical field, caffeine is used in the treatment of asthma and apnea in the newborns, in association with aspirin for headache, and in slimming compounds. Caffeine would inhibit lipid peroxidation and reduce the production of reactive oxygen species (ROS), so it would have a preventive role on neurodegenerative diseases (Devasagayam et al., 1996; Kolahdouzan & Hamadeh, 2017; Nehlig, 2010).

The properties of caffeine are still controversial. Indeed, if it seems to enhance working memory to a limited extent, especially in case of reduced alertness conditions, it can also impair this skill, so that it is concluded that caffeine does not improve recall and long-term memory (Nehlig, 2010). The only effect attributable to caffeine is the improvement of reaction time. With regard to emotional enhancement, low doses of caffeine may be of help in reducing anxiety and improving mood, while at high doses caffeine is associated with an increase in arousal, anxiety and nervousness. As a whole, therefore, caffeine should be considered a mild stimulant rather than a cognitive enhancer (Nehlig, 2010).

**Ginkgo biloba**

Ginkgo biloba extracts, whose active compounds are flavonoid glycosides and terpene lactones (Singh et al., 2014) seems to exert an antioxidant, anti-inflammatory action, as well as to play a modulating role in CNS (Zhang et al., 2017). Over the last decade, this compound has gained much attention, as different studies demonstrated that it might enhance cognitive functions in both animal models and healthy individuals (Abdel-Wahab & Abd El-Aziz, 2012; Alkuraishy et al., 2014). A study on 30 healthy subjects taking ginkgo biloba (60 mg/die for four days), found that it improved psychometric reaction time and cognitive central integrity, as assessed by the Leeds Psychomotor Test and Critical fusion-flicker threshold, respectively, although memory resulted unchanged (Alkuraishy et al., 2014).

**Hypericum perforatum**

Hypericum perforatum, better known as St. John’s wort, is commonly used to treat depression given its serotonergic activity (Calapai et al., 2001), however, its antidepressant efficacy is not wholly confirmed (Grobler et al., 2014). Similarly, its effects as cognitive enhancer, studied mainly in animal models, remain controversial (Ben-Elizee & Yechiam, 2016; Valvassori et al., 2018).

Soft enhancers are widely used among students. Higher percentages of users were reported in a sample of students of German universities, with almost 90% of participants reporting to take caffeine as a non-prescription stimulant, both as caffeinated beverages and caffeine tablets (11.1%). Approximately a quarter of the participants consumed legal herbal drugs (valerian, ginkgo biloba, St. John’s wort with the greater proportion of users being women (p < 0.001) (Eickenhorst et al., 2012). Reasons reported for using this kind of neuroenhancers include improving performance, although about 60% of participants believed that neuroenhancers may have consequences on health, including psychological addiction (Eickenhorst et al., 2012). Similar prevalence rates were reported by a Dutch study on university students, with approximately 90% of the sample (n=1,503) reporting to use soft enhancers for non-medical use, and 45% specifically for cognitive enhancement (Schelle et al., 2015). Also, as reported by...
Table 6. Soft enhancers – Prevalence among college students, reasons for use and impact on cognition

| Authors and year | Type              | N     | Enhancer                                      | Method                                 | Results                                                                 |
|------------------|-------------------|-------|-----------------------------------------------|----------------------------------------|-------------------------------------------------------------------------|
| Perkin et al., 2002 | Cross-sectional   | 1000  | Nonvitamin, nonmineral supplements            | 15-item questionnaire                  | Lifetime use of dietary supplements (6.3%), with ginseng (29.7%), echinacea (27.8%), protein/amino acids (22.8%). Reason for use: improve energy 61.2%, promote weight loss 38%, to relieve stress and improve mood 24.7%, improve memory 17.5% echinacea (45%), ginseng (34%), ginkgo biloba (22%), garlic (15%), St. John’s wort (14%), peppermint (14%), ginger (10%), chamomile, (9%), kava kava (9 %), and ephedra (7 %) |
| Gardiner et al., 2007 | Cross-sectional   | 31044 | Herbal dietary supplements                    | National Health Interview Survey       | Use of caffeine during study period, 89.3% (beverages), 11.7% (pills), herbal drugs 25.2%. Reason for use: improve concentration 55%, increase vigilance 49%, enhance cognitive potential 43%, cope with stress 38%. |
| Eickenhorst et al., 2012 | Cross-sectional   | 1218  | Caffeine beverages and pills, herbal drugs (valerian, ginkgo biloba, hypericum perforatum) | Online survey                          | Use of energy drinks, 39.2% at least one a week. Social reasons, enhancement and coping were the most common reason for use |
| Skewes et al., 2013 | Cross-sectional   | 298   | Energy drink                                  | Paper-and-pencil self-report questionnaire | Use of lifestyle drugs as cognitive enhancers 45.6%                      |
| Shelle et al., 2015 | Cross-sectional   | 1503  | Lifestyle drugs (alcohol, nicotine, caffeine, over the counter pharmacy products) | Online survey                          | Use of energy drink, 51%                                                |
| Malinauskas et al., 2016 | Cross-sectional   | 496   | Energy drink                                  | Ad hoc 19-item questionnaire            | Use of energy drink, 51%                                                |
| Kusturica et al., 2019 | Cross-sectional   | 214   | Caffeine, energy drink, over the counter drugs | Ad hoc questionnaireWest-side test anxiety scale (WTAS) | Emotion dysregulation predicted drinking coping motives                  |

| Authors and year | Type              | N     | Method                                   | Results                                                                                                         |
|------------------|-------------------|-------|------------------------------------------|------------------------------------------------------------------------------------------------------------------|
| Neligh et al., 2010 | Narrative review   | -     | Non systematic review of literature      | ↓ working memory; ↑ (in case reduced alertness), ↔ recall and long-term memory, ↓ reaction time. ↓ anxiety, ↑ mood (low doses), ↑ arousal, anxiety and nervousness (high doses) |
| Abdel-Wahab et al., 2012 | Case-control preclinical study | 80    | Intermittent hypoxia (n=40), Room air (n=040) Passive avoidance reflex test Biochemical assays | ↓ memory impairment induced by hypoxia                                                                                    |
| Al-Kuraishy et al., 2014 | Clinical trial   | 30    | Leeds psychomotor tester (CFFT) Critical fusion -flicker threshold, Computerized N-Back Task | ↓ psychomometric reaction time, ↑ cognitive central integrity p<0.05 ↔ working memory accuracy                  |
| Ben Eliezer et al., 2016 | Meta-analysis     | -     | A Google Scholar structured search. No language, publication date, or publication status restrictions. 13 studies (published 2000–2014) were included. | reference memory and working memory ↑ healthy rodents, ↑ stress-impaired rodents.                                      |
a study on Bosnian-Herzegovinian first-year university students, consumption of soft enhancers, that involved 31% of students, tended to increase during the week before the exams (Kusturica et al., 2019).

In the USA, a study conducted in Alaska on college students (n=298) reported that approximately 40% of participants consumed energy drinks at least once per week. Social reasons were the most frequent, although “enhancement” and “coping” were also common motives for energy drink use. A negative association emerged between age and energy beverages consumption (Skewes et al., 2013). Another study on 496 college students of central region university, reported that half of the participants (51%) consumed energy drink regularly (more than one each month), with a light prevalence amongst female sex (Malinauskas, 2007).

According to the National Health Interview Survey (NHIS), past year prevalence of herb dietary supplements (HDS) in the country was approximately 17% (n=31,044 NHIS respondents). This habit was more common among older, higher income, college-educated, non-Hispanic ethnicity participants. The most used HDS were echinacea (45%), ginseng (34%), ginkgo biloba (22%), garlic (15%), St. John’s wort (14%), peppermint (14%), ginger (10%), chamomile, (9%), kava kava (9 %), and ephedra (7 %) (Gardiner et al., 2007). Although HDS were used mostly to treat medical conditions, including anxiety and insomnia, they are common also among college students. Indeed, as emerged in a sample of 1000 college students, more than one quarter (26.3%) reported a lifetime use of dietary supplements, with Ginseng, echinacea, protein/ amino acids being the most frequent used. Among HDS users, 61.2% reported taking them to “improve energy”, 38% to “promote weight loss”, 24.7% to “relieve stress and improve mood”, 17.5% to “improve memory”, 13.3% to “enhance sleep”. No ethnic, gender, health differences emerged amongst HDS users, although those who practice exercise more than three times per month and cigarette smoking were factors associated to HDS use (Perkin et al., 2002).

Table 7. Non-invasive transcranial brain stimulation and neurofeedback

| Authors and year | Type | N | Technique | Method | Results |
|------------------|------|---|-----------|--------|---------|
| Knoch et al., 2006 | Case-control study | 52 | Low-frequency repetitive transcranial magnetic stimulation (rTMS) | Ultimatum Game | Disruption of the right, but not the left, dorsolateral prefrontal cortex (DLPFC) by rTMS reduces subjects’ willingness to reject their partners’ intentionally unfair offers, which suggests that subjects are less able to resist the economic temptation to accept these offers |
| Young et al., 2010 | Repeated measures design controlled trial | - | Transcranial magnetic stimulation (TMS) to disrupt neural activity in the right temporoparietal junction (RTPJ) | Experiment 1: TMS transiently before moral judgment (offline stimulation); Experiment 2: TMS during moral judgment (online stimulation) | Interfering with activity in the RTPJ disrupts the capacity to use mental states in moral judgment, especially in the case of attempted harms |
| Hamilton et al., 2011 | Narrative review | - | Transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) | Non systematic literature review | Preliminary results in healthy individuals suggest a possible role of TMS and tDCS on cognition, mood and social skills |

Non-invasive transcranial brain stimulation

Non-invasive brain stimulation, including transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), aims at modifying brain activity. Thanks to a magnetic current, TMS may influence neuronal activity in cortical regions, according to the variation of frequencies leading to a reduced or increased excitability for low and high frequency, respectively. The tDCS employs weak electrical current that alters neuronal excitability depending on the polarity of current. Both TMS and tDCS are used to treat resistant psychiatric and neurological disorders, although their use is still limited (Hamilton et al., 2011; Thibaut et al., 2014).

With regard to healthy individuals, available data, albeit limited, do not seem to indicate that such techniques may boost cognitive performance and/or modify emotional status (Knoch et al., 2006; Young et al., 2010) (table 7).

Neurofeedback

Neurofeedback is a type of biofeedback consisting in teaching a subject how to self-regulate his/her brain activity. Neurofeedback techniques include electroencephalography (EEG), functional magnetic resonance imaging (fMRI) and spectroscopy. In particular EEG records cortical neuronal (Hammond, 2011), while fMRI shows activity of all cerebral regions (Weiskopf, 2012). Thanks to biofeedback techniques a subject can be aware of his/her neural activity and can learn how to modify it. So far, clinical indications of neurofeedback include ADHD and other developmental disorders, Parkinson’s disease, epilepsy, alcoholism, drug addictions, chronic pain, tinnitus, etc. (Hammond, 2011; Mihara et al., 2012; Weiskopf, 2012).

In healthy subjects, neurofeedback was found not only to improve cognitive performance, such as short term and working memory (Angelakis et al., 2007), learning, visuo-spatial skills or executive functions (Enriquez-Geppert et al., 2013), but also artistic performance (dancing, instrumental music, singing,
Neuroenhancement: state of the art and future perspectives

Clinical Neuropsychiatry (2021) 18, 3

Table 7. Continued

| Authors and year | Type                                      | N participants | Technique                                  | Method                                                                 | Results                  |
|------------------|-------------------------------------------|----------------|--------------------------------------------|------------------------------------------------------------------------|--------------------------|
| Angelakis et al., 2007 | Double-blind controlled design trial      | 6 elderly subjects | EEG peak alpha frequency (PAF)          | State-Trait Personality Inventory (STPI), Digit Span (Wechsler, 1995), the Word List Memory Task (Welsh, Butters, Hughes, Mohs, & Heyman, 1991), the Stroop test (Stroop, 1935), the Stroop Selective Inhibition test, Raven’s Standard Progressive Matrices, the Logical Memory, Faces, Verbal Paired Associates, Family Pictures, Visual Reproduction subtests of the Wechsler Memory Scale-III, “n-back” task and a “Go-No-Go” oddball task | ↑ cognitive processing speed and executive function, but that it had no clear effect on memory |
| Hammond, 2011     | Narrative review                          | -              | EEG biofeedback                           | Non systematic review of literature                                    | ↑ cognitive performance in healthy individuals |
| Enriquez-Geppert et al., 2013 | Narrative review                          | -              | Computerized behavioral training, neurofeedback and transcranial electrostimulation | Non systematic literature review                                      | ↑ performance in task switching, memory updating, and dual tasks. Behavioral benefits in response inhibition, task switching, and memory updating |

etc.) sports (golf, archery, etc.), and even surgery (Hammond, 2011). Beneficial effects of real-time fMRI neurofeedback (rt-fMRI-NF) have been reported, specifically increased positive emotion experiences in depressed and anxious patients (Linhartová et al., 2019).

However, the information on the possible neuroenhancing properties of neurofeedback is meager and should be considered preliminary.

Emotional enhancement

Emotional enhancement is that kind of neuroenhancement aiming at modifying an individual’s emotions by amplifying and/or enhancing emotional states beyond normal levels of intensity by natural or artificial means. Although this is not the main topic of our review, in the next paragraphs our focus will be on oxytocin and pheromones, natural compounds with promising properties in this sense (table 8).

Oxytocin

Oxytocin is a small neuropeptide composed of nine amino acids. It is mainly synthesized centrally, in the paraventricular and supraoptic nuclei of the hypothalamus, but also in other sites in the central nervous system, such as the stria terminalis, the anterior commissural nucleus and spinal cord, and in non-neural tissues including ovary, testis, adrenal, thymus, and pancreas (Buijs et al., 1983; Jenkins & Nussey, 1991; Sofroniew, 1983). Oxytocin plays a role in different physiological functions including labor, uterine dilatation, lactation, sexual stimulation, stress regulation and social behaviors (Carter et al., 2001; Jenkins & Nussey, 1991; Zeeman et al., 1997). In general oxytocin is considered a pro-social hormone as it seems to increase in-group trust, capacity of recognition of facial emotions, empathy, and to reduce anxiety and stress, while promoting health and wellbeing through its immunomodulatory effects (Domes et al., 2007; Heinrichs et al., 2003; Hurlemann et al., 2010; Kirsch et al., 2005; Marazziti et al., 2006; Shahrestani et al., 2013; Van IJzendoorn & Bakermans-Kranenburg, 2012). Not surprisingly, oxytocin has been hypothesized to be involved in the pathophysiology of different psychiatric disorders and to constitute a novel and natural treatment (Marazziti & Catena Dell’Osso, 2008). Indeed, nasal spray of oxytocin was found to improve social deficits in autism, by increasing eye contacts, decision-making and emotion understanding, and to achieve beneficial effects on repetitive behaviors and feelings of avoidance (Andari et al., 2010; Bernaerts et al., 2017; Bernaerts et al., 2020; Guastella et al., 2010; Yatabara et al., 2016). For its role in social bonding, over the last decades oxytocin has gained increasing attention until being regarded as a “love hormone” that might be helpful to resolve relationship problems, sexual difficulties or even to find a partner (Olff et al., 2013). Far from being a ‘love potion’, oxytocin may truly facilitate interpersonal intimacy or approach to partner, empathy and perhaps help to maintain a pair bond (Aruei et al., 2013; Heinrichs et al., 2003).

According to Wudarczyk et al. (2013), oxytocin should be used within a context of a structured treatment plan only if both partners agree to the treatment (Wudarczyk et al., 2013). However, we would underline that bond-promoting compounds involve the risk for excessive “medicalization” of human relationships and feelings, such as love, while scrambling their authenticity (Davis, 2010; Earp et al., 2015). Although data on the benefits of oxytocin are too limited before firm conclusions should be drawn, research in this field is active, so that these are questions that require to be answered soon.
According to different studies, pheromones may modulate human sexual behavior, including axillary and pubic region (Grammer et al., 2005). Androstadienone (100 pg) and 18 ng propylene glycol were found to improve self-injuring behavior, social and separation anxiety symptoms of bipolar disorder, autism, OCD and reduce mood swings. Although just a few case reports have been published, pheromones, the so-called appeasing pheromones (APs), might be useful in treatment of psychiatric disorders (Doucet et al., 2009). Although just a few case reports are reported in the literature, APs was found to improve symptoms of bipolar disorder, autism, OCD and reduce self-injuring behavior, social and separation anxiety (Piccinni et al., 2018). In any case, the role of pheromones in human (patho)physiology, that seems intriguing, is still controversial and requires to be deepened in future studies (Liebowitz et al., 2014; Winman, 2004; Wyart et al., 2007).

### Table 8. Emotional enhancer

| Authors and year | Type | N participants | Emotional enhancer | Method | Results |
|------------------|------|----------------|--------------------|--------|---------|
| **Oxytocin**     |      |                |                    |        |         |
| Arueti et al., 2013 | Double-blind placebo-controlled within-subject crossover design trial | 42 | Intranasal oxytocin (24 U.I.) | “Etch-a-Sketch” Task | ↑ paired performance up to the level of individual performance |
| Heinrichs et al., 2003 | Randomized, double-blind, placebo-controlled trial | 37 | Intranasal oxytocin (24 U.I.) | Trier Social Stress Test | ↓ salivary free cortisol levels in case social support in response to stress |
| **Pheromones**   |      |                |                    |        |         |
| Kirk-Smith et al., 1978 | Case-control study | 24 | Androstenol (0.3 mg) | 16 photographs rated with nine-point bipolar category scales | Androstenol group rated the photographed women as sexier and more attractive |
| Benton, 1982 | Randomized, double-blind, placebo-controlled trial | 18 | 5α-androst-16-en-3α-ol (150 mg) | Menstrual distress questionnaire, Rating scales consisting about psychological distress | ↔ ratings of being happy/depressed; lethargic/lively sexy/unsexy; irritable/good-tempered |
| Grosser et al., 2000 | Double-blind randomized parallel 22 design at a rate of one or two per day trial | 40 | Androstadienone (100 pg) and 18 ng propylene glycol | Derogatis Inventory | ↓ nervousness, tension and other negative feeling states |
| Jacob and McClintock, 2000 | Experiment 1: randomized, double-blind, placebo-controlled, within-subject design trial | Experiment 1: 20 | Experiment 2: Δ4,16-androstadien-3-one (A; 0.00025 M concentration in propylene glycol or PG) and 1,3,5,(10),16-estratetraen-3-ol (E; 0.00025 M concentration in PG), or carrier odorant alone (PG) | The Profile of Mood States (POMS), The Addiction Research Center Inventory (ARCI), Visual Analog Scales (VAS) | ↑ positive stimulated mood state in women but decreased it in men Experiment 2: Δ4,16-androstadien-3-one modulated their general mood state, even when women were not aware of its odor. |

**Pheromones**

The term pheromones, first used by Karlson and Lüscher in 1959, refers to a chemicals capable of convey information, triggering endocrine, behavioral and developmental reactions amongst conspecifics, including mammals (Brennan & Keverne, 2004; Karlson & Luscher, 1959). The vomeronasal organ (VNO), a specialized area of olfactory system that is also present in humans, is where pheromones are detected (Monti-Bloch & Grosser, 1959). The vomeronasal organ (VNO), a specialized area of olfactory system that is also present in including mammals (Brennan & Keverne, 2004; Karlson & Luscher, 1959). The vomeronasal organ (VNO), a specialized area of olfactory system that is also present in including mammals (Brennan & Keverne, 2004; Karlson & Luscher, 1959). The vomeronasal organ (VNO), a specialized area of olfactory system that is also present in including mammals (Brennan & Keverne, 2004; Karlson & Luscher, 1959). The vomeronasal organ (VNO), a specialized area of olfactory system that is also present in including mammals (Brennan & Keverne, 2004; Karlson & Luscher, 1959). The vomeronasal organ (VNO), a specialized area of olfactory system that is also present in including mammals (Brennan & Keverne, 2004; Karlson & Luscher, 1959). The vomeronasal organ (VNO), a specialized area of olfactory system that is also present in including mammals (Brennan & Keverne, 2004; Karlson & Luscher, 1959). The vomeronasal organ (VNO), a specialized area of olfactory system that is also present in including mammals (Brennan & Keverne, 2004; Karlson & Luscher, 1959). The vomeronasal organ (VNO), a specialized area of olfactory system that is also present in including mammals (Brennan & Keverne, 2004; Karlson & Luscher, 1959). The vomeronasal organ (VNO), a specialized area of olfactory system that is also present in including mammals (Brennan & Keverne, 2004; Karlson & Luscher, 1959). The vomeronasal organ (VNO), a specialized area of olfactory system that is also present in
Neuroenhancement: state of the art and future perspectives

Clinical Neuropsychiatry (2021) 18, 3

↑ mood, sexual

4,16-androstadien-3-one

3-methyl-2-hexenoic acid (3M2H) (0.5 mg/ml), (male axillary extracts)

7-point, Likert-type, categorical scale

↓ tension, ↑ relaxation

Table 8. Continued

| Pretti et al., 2003 | Double-blind, repeated measures design trial | 18 | 3-methyl-2-hexenoic acid (3M2H) (0.5 mg/ml), (male axillary extracts) | 7-point, Likert-type, categorical scale | ↓ tension, ↑ relaxation |
|-------------------|---------------------------------------------|----|---------------------------------------------------------------|-----------------------------------------------|------------------------|
| Lündstrom et al., 2003 | Experiment 1: randomized, double-blind, placebo-controlled, between-groups design trial | Experiment 1: randomized, double-blind, placebo-controlled, between-groups design trial | Experiment 1: Androstadienone 250 M concentration of androstadienone (A) in mineral oil (M) with an odor mask consisting of 1% eugenol (E) | Experiment 1: State Trait Anxiety Inventory-State (STAI-S) and the State Trait Anxiety Inventory- Trait (STAI-T) | Experiment 1: ↔ mood |
| Bensafi et al., 2004 | Randomized, placebo-controlled, between-subject design study | Randomized, placebo-controlled, between-subject design study | 4,16-androstadien-3-one (Low concentration 2 mg, high concentration 50 mg) | 16-item test | ↑ positive mood and decreased negative mood in women compared to men (high concentrations) |
| Wyart et al., 2007 | Double-blind, within-subjects repeated-measures design | Double-blind, within-subjects repeated-measures design | 4,16-androstadien-3-one (30 mg) | 17-item scale | ↑ mood, sexual arousal, and physiological arousal |
| Marazziti et al., 2010 | Randomized, double-blind, placebo-controlled trial | Randomized, double-blind, placebo-controlled trial | Male axillary underarm extracts | The “Experiences in Close Relationships” questionnaire (ECR), the latest version of the Barratt Impulsiveness Scale (BIS-11), Structured Clinical Interview for Mood Spectrum, self-reported version (SCI-MOOD last month) | Impact on impulsiveness and romantic attachment |

Conclusions: ethical implications

In spite of the limited evidence that some substances may improve cognitive functions in healthy subjects, there is an increasing worldwide use of the so-called neuroenhancers. If those included in the category of soft enhancers are not dangerous, as most of them produce placebo-like effects, it is astonishing how students and workers in competitive settings use active drugs, apparently neglecting or underestimating their detrimental side effects and potential risk of misuse, abuse and addiction. However, it is true that human beings are embedded by the wish to overcome their physical and cognitive constraint, and to expand their knowledge, mind and consciousness far beyond the nature-imposed limits. According to some authors, our history is mostly an improvement history (Buchanan, 2012), with a constant increase of human capacities and of quality of life (Caplan, 2003; Savulescu, 2006) that permitted to overcome difficulties of hostile environments, to evolve and to achieve a constant progression in artistic, technological and scientific domains.

Taken to the extreme positions, however, this approach led transhumanists and posthumanists considering licit every natural, chemical or technological mean to expand human skills, abilities and opportunities (Bostrom, 2003). On the other pole, the bioconservative approach is focused on preserving authenticity of human nature and considers neuroenhancers as a threat that can only result in unnatural outcomes (Fukuyama, 2002; Sandel, 2004). According to the “ethics of authenticity”, theorized by the Canadian philosopher Charles Taylor, everyone should yearn to self-perfection and do its best to actualize its hidden potential (Taylor, 1991; Kraemer, 2011). Those who are not able to reach self-actualization are thought inadequate and unworthy of having a satisfying life (Elliott et al., 1997; Elliott, 2000; Taylor, 1991). In recent days, the concept of ‘authenticity’ has acquired a predominant role in ethical issues concerning ‘human enhancement’, as people tend to use enhancement in order to reach their personal authenticity. Obviously, the matter is complex, deeply debated, with most of its questions that remain largely unresolved.

With no doubt, more reliable studies carried out with no prejudice on effects of neuroenhancement in healthy subjects will be helpful in clarifying some, if not all issues. If it were licit or not to expand our cognitive and emotional abilities up to the point of scrambling our authenticity is a question requiring an integrated approach from specialists of different disciplines, from psychology to psychiatry, philosophy, religion, social and political science.
References

Abdel-Wahab, B. A., & Abd El-Aziz, S. M. (2012). Ginkgo biloba protects against intermittent hypoxia-induced memory deficits and hippocampal DNA damage in rats. *Phytotherapy Research, 19*(5), 444-450. https://doi.org/10.1016/j.phymed.2011.11.011

Ahmed, A. H., & Oswald, R. E. (2010). Piracetam defines a new binding site for allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors. *Journal of Medicinal Chemistry, 53*(5), 2197-2203. https://doi.org/10.1021/jm901905j

Alkuraisy, H. M., Alqareem, A. I., Alalhuaddily, A. K., & Almgoter, B. M. (2014). Modulation effects of piracetam and Ginkgo biloba on the cognitive and working memory functions: Psychometric study. *Journal of Neurology & Neuropsychrophysicsiology, 5*(5), 234. https://doi.org/10.4172/2155-9562.1000234

Andari, E., Duhamel, J. R., Zalla, T., Herbrecht, E., Leboyer, M., & Sirigu, A. (2010). Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. *Proceedings of the National Academy of Sciences of the United States of America, 107*(9), 4389-4394. https://doi.org/10.1073/pnas.0910249107

Anderson, T., Petranek, R., Rosenbaum, D., Weissman, C. R., Ding-Williams, L. A., Hui, K., Hapke, E., & Farb, N. (2019). Microdosing psychedelics: Personality, mental health, and creativity differences in microdosing. *Psychopharmacology, 236*(2), 731-740. https://doi.org/10.1007/s00213-018-5106-2

Angelakis, E., Stathopoulou, S., Frymiare, J. L., Green, D. L., Lubar, J. F., & Kounios, J. (2007). EEG neurofeedback: A brief overview and an example of peak alpha frequency training for cognitive enhancement in the elderly. *The Clinical Neuropsychologist, 21*(1), 110-129. https://doi.org/10.1080/13854040600744839

Arria, A. M., Caldeira, K. M., O'Grady, K. E., Vincent, K. B., Johnson, E. P., & Wish, E. D. (2008). Nonmedical use of prescription stimulants among college students: Associations with attention-deficit-hyperactivity disorder and polydrug use. *Pharmacotherapy, 28*(2), 156-169. https://doi.org/10.1592/phco.28.2.156

Arasti, M., Perach-Barzilay, N., Tsory, M. M., Berger, B., Getter, N., & Shanay-Tsory, S. G. (2013). When two become one: The role of oxytocin in interpersonal coordination and cooperation. *Journal of Cognitive Neurosciences, 25*(9), 1418-1427. https://doi.org/10.1162/jocn_a_00400

Bae, H., & Kerr, D. (2020). Marijuana use trends among college students in states with and without legalization of recreational use: Initial and longer-term changes from 2008 to 2018. *Addiction (Abingdon, England), 115*(6), 1115-1124. https://doi.org/10.1111/add.14939

Bagot, K. S., & Kaminer, Y. (2014). Efficacy of stimulants for cognitive enhancement in non-attention deficit hyperactivity disorder youth: A systematic review. *Addiction (Abingdon, England), 109*(4), 547-557. https://doi.org/10.1111/add.12466

Barnford, S., Penton-Voak, I., Pinkeyn, V., Baldwin, D. S., Munafò, M. R., & Garnier, M. (2015). Early effects of duloxetine on emotion recognition in healthy volunteers. *Journal of Psychopharmacology, 29*(5), 634-641. https://doi.org/10.1177/0269881115570085

Baranski, J. V., & Pigeau, R. A. (1997). Self-monitoring cognitive performance during sleep deprivation: Effects of modafinil, d-amphetamine and placebo. *Journal of Sleep Research, 5*(2), 84-91. https://doi.org/10.1111/j.1365-2869.1997.tb0012.x

Barnes, C. A., Danyasz, W., & Parsons, C. G. (1996). Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. *The European Journal of Neuroscience, 8*(3), 565-571. https://doi.org/10.1111/j.1460-9568.1996.tb01241.x

Becker, M. P., Collins, P. F., & Luciana, M. (2014). Neurocognition in college-aged daily marijuana users. *Journal of Clinical and Experimental Neuropsychology, 36*(4), 379-398. https://doi.org/10.1080/13803395.2014.893966

Bensafi, M., Brown, W. M., Khan, R., Levenson, B., & Sobel, N. (2004). Sniffing human sex-steroid derived compounds modulates mood, memory and autonomic nervous system function in specific behavioral contexts. *Behavioural Brain Research, 152*(1), 11-22. https://doi.org/10.1016/j.bbr.2003.09.009

Benton, D. (1982). The influence of androstened - a putative human pheromone - on mood throughout the menstrual cycle. *Biological Psychology, 15*(3-4), 249-256. https://doi.org/10.1016/0301-0511(82)90047-3

Ben-Elizeier, D., & Yechiam, E. (2016). Hypericum perforatum as a cognitive enhancer in rodents: A meta-analysis. *Scientific Reports, 6*, 35700-35700. https://doi.org/10.1038/srep35700

Bernaerts, S., Boets, B., Bosmans, G., Steyaert, J., & Alaerts, K. (2020). Behavioral effects of multiple-dose oxytocin treatment in autism: A randomized, placebo-controlled trial with long-term follow-up. *Molecular Autism, 11*(1), 6. https://doi.org/10.1186/s13229-020-0313-1

Bernaerts, S., Prinsen, J., Berra, E., Bosmans, G., Steyaert, J., & Alaerts, K. (2017). Long-term oxytocin administration enhances the experience of attachment. *Psychoonreodocrinology, 78*, 1-9. https://doi.org/10.1016/j.psyneuen.2017.01.010

Bigos, K. L., Pollock, B. G., Aizenstein, H. J., Fisher, P. M., Bies, R. R., & Hariri, A. R. (2008). Acute 5-HT reuptake blockade potentiates human amygdala reactivity. *Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 33*(13), 3221-3225. https://doi.org/10.1038/npp.2008.52

Birks, J. (2006). Cholinesterase inhibitors for Alzheimer's disease. *The Cochrane Database of Systematic Reviews, 1*(CD005593). https://doi.org/10.1002/14651858.CD005593

Bonar, E. E., Goldstick, J. E., Collins, R. L., Cranford, J. A., Cunningham, R. M., Cermack, S. T., Blow, F. C., & Walton, M. A. (2017). Daily associations between cannabis motives and consumption in emerging adults. *Drug and Alcohol Dependence, 178*, 136-142. https://doi.org/10.1016/j.drugalcdep.2017.05.006

Bostrom, N. (2003). Human genetic enhancements: A transhumanist perspective. *The Journal of Value Inquiry, 37*(4), 493-506. https://doi.org/10.1023/b:iniq.0000019037.67783.d5

Brandão, F., Paula-Barbosa, M. M., & Cadete-Leite, A. (1995). Piracetam impedes hippocampal neuronal loss during withdrawal after chronic alcohol intake. *Alcohol (Fayetteville, N.Y.), 12*(3), 279-288. https://doi.org/10.1016/0741-8329(94)00107-0

Bravo, A. J., Prince, M. A., Pearson, M. R., & Marijuana Outcomes Study Team (2017). Can I use marijuana safely? *Clinical Neuropsychologist, 21*(1), 33. https://doi.org/10.1186/s13229-017-0312-1

Brennan, S. E., McDonald, S., Page, M. J., Reid, J., Ward, S., Forbes, A. B., & McKenzie, J. E. (2020). Long-term effects of alcohol consumption on cognitive function: A systematic review and dose-response analysis of evidence published between 2007 and 2018. *Systematic Reviews, 9*(1), 33. https://doi.org/10.1186/s13643-019-1220-4
effects of androstadienone, a human pheromone. *Psychoneuroendocrinology*, 25(3), 289-299. https://doi.org/10.1016/s0306-4539(99)00056-6

Grossman, L., Stewart, A., Gaikwad, S., Utterback, E., Wu, N., Dileo, J., Frank, K., Hart, P., Howard, H., & Kaluueff, A. V. (2011). Effects of piracetam on behavior and memory in adult zebrafish. *Brain Research Bulletin*, 85(1-2), 58-63. https://doi.org/10.1016/j.brbral.2011.02.008

Gründer, G., & Bartsch, T. (2014). Neuroenhancement. *Der Nervenarzt*, 85(12), 1536-1543. https://doi.org/10.1007/s00115-013-3977-3

Guastella, A. J., Einfeld, S. L., Gray, K. M., Rinehart, N. J., Tonge, B. J., Lambert, T. J., & Hickie, I. B. (2010). Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. *Biological Psychiatry*, 67(7), 692-694. https://doi.org/10.1016/j.biopsych.2009.09.020

Hall, K. M., Irwin, M. M., Bowman, K. A., Frankenberger, W., & Jewett, D. C. (2005). Illicit use of prescribed stimulant medication among college students. *Journal of American College Health : J of ACH*, 53(4), 167-174. https://doi.org/10.3200/JACH.53.4.167-174

Halpern, J. H., Sherwood, A. R., Hudson, J. I., Yurgelun-Todd, D., & Pope, H. G., Jr (2005). Psychological and cognitive effects of long-term peyote use among Native Americans. *Biological Psychiatry*, 58(8), 624-631. https://doi.org/10.1016/j.biopsych.2005.03.030

Hamilton, M. C., Messing, S., & Chatterjee, A. (2011). Rethinking the thinking cap: Ethics of neural enhancement using noninvasive brain stimulation. *Neurology*, 76(2), 187-193. https://doi.org/10.1212/WNL.0b013e318205d5d0

Hammond, D. C. (2011). What is neurofeedback: An update. *Journal of Neurotherapy: Investigations in Neuromodulation, Neurofeedback and Applied Neuroscience*, 15(4), 305-336. https://doi.org/10.1080/10874208.2011.623090

Hanson, C. L., Burton, S. H., Giraud-Carrier, C., West, J. H., Barnes, M. D., & Hansen, B. (2013). Tweaking and tweeting: Exploring Twitter for nonmedical use of a psychostimulant drug (Adderall) among college students. *Journal of Medical Internet Research*, 15(4), e62. https://doi.org/10.2196/jmir.2503

Harmer, C. J., Bhagwagar, Z., Perrett, D. I., Völlm, B. A., Cowen, P. J., & Goodwin, G. M. (2003b). Acute SSRI administration modifies the neural processing of nonconscious threat cues. *The American Journal of Psychiatry*, 160(5), 990-992. https://doi.org/10.1176/ajp.160.5.990

Harmer, C. J., Mackay, C. E., Reid, C. B., Cowen, P. J., & Goodwin, G. M. (2006). Antidepressant drug treatment and expenditure intentions for Schoolies. *Journal of Medical Ethics*, 32(6), 372-375. https://doi.org/10.1136/jmedethics-2011-100041

Hofmeister, S., & Bodden, S. (2016). Premenstrual syndrome and premenstrual dysphoric disorder. *American Family Physician*, 94(3), 236-240.

Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., Davis, J., Salanti, G., & Leucht, S. (2019). Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. *Lancet (London, England)*, 394(10202), 939-951. https://doi.org/10.1016/S0140-6736(19)31135-3

Hutten, N., Mason, N. L., Dolder, P. C., & Kuypers, K. (2019). Motives and side-effects of microdosing with psychedelics among users. *The International Journal of Neuropsychopharmacology*, 22(7), 426-434. https://doi.org/10.1093/ijnppyj029

Hwang, K., & Saadabadi, A. (2020). Lysergic Acid Diethylamide (LSD). In StatPearls. StatPearls Publishing.

Hysek, C. M., Schmid, Y., Simmler, L. D., Domes, G., Heinrichs, M., Eisenegger, C., Preller, K. H., Quadlew, B. B., & Liechti, M. E. (2014). MDMMA enhances emotional empathy and prosocial behavior. *Social Cognitive and Affective Neuroscience*, 9(11), 1645-1652. https://doi.org/10.1093/scan/nst161

Ilgseid, B. (2018). Doping für das Gehirn [Doping for the brain]. *Zeitschrift für Gerontologie und Geriatrie*, 51(2), 143-148. https://doi.org/10.1007/s00391-017-1351-y

Iliescu, I. P., & Farris, M. J. (2013). Enhancement stimulants: Perceived motivational and cognitive advantages. *Frontiers in Neuroscience*, 7, 198. https://doi.org/10.3389/fnins.2013.00198

Jackson, E. R., Shanafelt, T. D., Hasan, O., Satele, D. V., & Dyrbye, L. N. (2016). Burnout and alcohol abuse/dependence among U.S. medical students. *Academic Medicine : Journal of the Association of American Medical Colleges*, 91(9), 1251-1256. https://doi.org/10.1097/ACM.0000000000001138

Jacob, S., & McClintock, M. K. (2000). Psychological state and mood effects of steroidal chemosignals in women and men. *Hormones and Behavior*, 37(1), 57-78. https://doi.org/10.1006/hbeh.1999.1559

Jenkins, J. S., & Nussey, S. S. (1991). The role of oxytocin: Present concepts. *Clinical Endocrinology*, 34(6), 515-525. https://doi.org/10.1111/j.1365-2265.1991.tb00333.x

Jongenelis, M. I., Pettigrew, S., Biagioni, N., & Hagger, M. S. (2017). Western Australian students’ alcohol consumption and expenditure intentions for Schoolies. *Australian Journal of Primary Health*, 23(3), 268-271. https://doi.org/10.1071/YP16104

Juengst, E. T. (1998). What does enhancement mean? In E. Juengst, E.T. (Ed.). Present concepts. *Clinical Endocrinology*, 34(6), 515-525. https://doi.org/10.1111/j.1365-2265.1991.tb00333.x

Kaelen, M., Barrett, F. S., Roseman, L., Lorenz, R., Family, N., Bolstridge, M., Curran, H. V., Fielding, A., Nutt, D. J., & Carhart-Harris, R. L. (2015). LSD enhances the emotional cortisol and subjective responses to psychosocial stress. *Biological Psychiatry*, 74(12), 1389-1398. https://doi.org/10.1016/j.biopsych.2015.06.038

Heinz, A., Kипке, R., Heimann, H., & Wiesing, U. (2012). Cognitive neuroenhancement: False assumptions in the ethical debate. *Journal of Medical Ethics*, 38(6), 372-375. https://doi.org/10.1136/jmedethics-2011-100041

Clinical Neuropsychiatry (2021) 18, 3
response to music. Psychopharmacology, 232(19), 3607-3614. https://doi.org/10.1007/s00213-015-4014-y
Kandiah, N., Pai, M. C., Senanarong, V., Looi, L., Ampil, E., Park, K. W., Karaman, A. K., & Christopher, S. (2017). Rivastigmine: The advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia. Clinical Interventions in Aging, 12, 697-707. https://doi.org/10.2147/CIA.S129145
Karlsson, P., & Luscher, M. (1959). ‘Pheromones’: A new term for a class of biologically active substances. Nature, 183(4653), 55-56. https://doi.org/10.1038/183055a0
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjian, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., McNerney, J. S., McIntosh, D., Milev, R. V., Müller, D. J., Patirck, S. V., Pearson, N. L., Ravindran, A. V., Uher, R., & CANMAT Depression Work Group (2016). Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological treatments. Canadian Journal of Psychiatry: Revue Canadienne de Psychiatrie, 61(9), 540-560. https://doi.org/10.1177/0706743716659417
Kirkpatrick, M., Delton, T. E., & de Wit, H. (2015). Prosocial effects of MDMA: A measure of generosity. Journal of Psychopharmacology (Oxford, England), 29(6), 668-678. https://doi.org/10.1177/0269881115573806
Kirk-Smith, M., Booth, D. A., Carroll, D., & Davies, P. (1978). Drinking motives and links to alcohol use in Australian students: Prevalence and correlates of use. Alcohol and Drugs, 33(2), 173-188. https://doi.org/10.1175/mina-2016-0014
Liewbowitz, M. R., Salman, E., Nicolini, H., Rosenthal, N., Hanover, R., & Monti, L. (2014). Effect of an acute intranasal aerosol dose of PH94B on social and performance anxiety in women with social anxiety disorder. The American Journal of Psychiatry, 171(6), 675-682. https://doi.org/10.1176/appi.ajp.2014.12101342
Lieber, M. E. (2017). Modern clinical research on LSD. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 42(11), 2114-2127. https://doi.org/10.1038/npp.2017.86
Linhartová, P., Látlavová, A., Káša, B., Kašpárek, T., Schmahl, C., & Paret, C. (2019). fMRI neurofeedback in emotion regulation: A literature review. NeuroImage, 193, 75-92. https://doi.org/10.1016/j.neuroimage.2019.03.011
Linnser, A. M., Vuoristo, E. F., Salmi, A., & Riedel, W. J. (2012). Methylphenidate produces selective enhancement of declarative memory consolidation in healthy volunteers. Psychopharmacology, 221(4), 611-619. https://doi.org/10.1007/s00211-011-2605-9
Lipton, S. A., & Rosenberg, P. A. (1994). Excitatory amino acids as a final common pathway for neurologic disorders. The New England Journal of Medicine, 330(9), 613-622. https://doi.org/10.1056/NEJM1994030333030909
Luce, J., Jensen, C., Dunn, M., Chan, G., Forlini, C., Kaye, S., Partridge, B., Farrell, M., Racine, E., & Hall, W. (2018). Non-medical prescription stimulant use to improve academic performance among Australian university students: Prevalence and correlates of use. BMC Public Health, 18(1), 1270. https://doi.org/10.1186/s12889-018-6212-0
Lundström, J. N., Gonçalves, M., Esteves, F., & Olsson, M. J. (2003). Psychological effects of subthreshold exposure to the putative human pheromone 4,16-androstadien-3-one. Hormones and Behavior, 44(5), 395-401. https://doi.org/10.1016/j.yhbeh.2003.06.004
Mache, S., Eickenhorst, B., Vitzthum, K., Klapp, B. F., & Groneberg, D. A. (2012). Cognitive-enhancing substance use at German universities: Frequency, reasons and gender differences. Wiener Medizinische Wochenschrift (1946), 162(11-12), 262-271. https://doi.org/10.1007/s10354-012-0115-y
Magrys, S. A., & Olmstead, M. C. (2015). Acute stress increases voluntary consumption of alcohol in undergraduates.
Neuroenhancement: state of the art and future perspectives

Clinical Neuropsychiatry (2021) 18, 3

US college students: Prevalence and correlates from a national survey. *Addiction (Abingdon, England)*, 106(1), 96-106. https://doi.org/10.1111/1360-0443.2005.00944.x

McDaniel, M. A., Maier, S. F., & Einstein, G. O. (2002). "Brain-specific" nutrients: A memory cure? *Psychological Science in the Public Interest: A Journal of the American Psychological Society*, 3(1), 12-38. https://doi.org/10.1111/1529-1006.00007

McKenna, D. J., Repke, D. B., Lo, L., & Peroutka, S. J. (1990). Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes. *Neuropsychopharmacology*, 29(3), 193-198. https://doi.org/10.1016/0282-3908(90)90001-8

Mckie, S., Del-Ben, C., Elliott, R., Williams, S., del Vai, N., Anderson, I., & Deakin, J. F. (2005). Neuronal effects of acute citolopram detected by pharmacoMRI. *Psychopharmacology*, 179(4), 680-686. https://doi.org/10.1007/s00213-005-2270-3

McShane, R., Arreosa Sastre, A., & Minakaran, N. (2006). Memantine for dementia. *The Cochrane Database of Systematic Reviews*, (2), CD003154. https://doi.org/10.1002/14651858.CD003154.pub5

Mehta, M. A., Owen, A. M., Sahakian, B. J., Mavaddat, N., Pickard, J. D., & Robbins, T. W. (2000). Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience*, 20(6), RC65. https://doi.org/10.1523/JNEUROSCI.20-06-00042.2000

Messor-Moore, T. L., Walsh, K. L., & DiLillo, D. (2010). Emotion dysregulation and risky sexual behavior in revictimization. *Child Abuse & Neglect*, 34(12), 967-976. https://doi.org/10.1016/j.chiabu.2010.06.004

Micoaulaud-Franchi, J. A., MacGregor, A., & Fond, G. (2014). A preliminary study on cognitive enhancer consumption behaviors and motives of French Medicine and Pharmacology students. *European Review for Medical and Pharmacological Sciences*, 18(13), 1875-1878.

Middendorff, E., Apolinarski, B., Becker, K., Bornkessel, P., Brandt, T., Heifenberg, S., & Poskowski, J. (2017). Die wirtschaftliche und soziale Lage der Studierenden in Deutschland 2016. Zusammenfassung zur 21. Sozialerhebung des Deutschen Studentenwerks – durchgeführt vom Deutschen Zentrum für Hochschul- und Wissenschaftsforschung. Berlin: Bundesministerium für Bildung und Forschung (BMBF).

Mihara, M., Miyai, I., Hattori, N., Hatakenaka, M., Yagura, H., Kawano, T., Okibayashi, M., Danjo, N., Ishikawa, A., Inoue, Y., & Kubota, K. (2012). Neurofeedback using real-time near-infrared spectroscopy enhances motor imagery related cortical activation. *PloS One*, 7(3), e32234. https://doi.org/10.1371/journal.pone.0032234

Miller, D. D. (2004). Atypical antipsychotics: Sleep, sedation, and efficacy. *Primary Care Companion to the Journal of Clinical Psychiatry*, 6(Suppl 2), 3-7.

Mindus, P., Cronholm, B., Levander, S. E., & Schalling, D. (1976). Piracetam-induced improvement of mental performance. A controlled study on normally aging individuals. *Acta Psychiatrica Scandinavica*, 54(2), 150-160. https://doi.org/10.1111/j.1600-0447.1976.tb00107.x

Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *PLoS Medicine*, 6(7), e1000097. https://doi.org/10.1371/journal.pmed.1000097

Monti-Bloc, L., & Grosser, B. I. (1991). Effect of putative pheromones on the electrical activity of the human vomeronasal organ and olfactory epithelium. *The Journal of Steroid Biochemistry and Molecular Biology*, 39(4B), 573-582. https://doi.org/10.1016/0960-0760(91)90255-4

Monti-Bloc, L., Jennings-White, C., & Berliner, D. L. (1998).
The human vomaneral system. A review. *Annals of the New York Academy of Sciences*, 853, 373–389. https://doi.org/10.1111/j.1749-6632.1998.tb10595.x

Mucci, F., Avella, M. T., & Marazziti, D. (2019). ADHD with comorbid bipolar disorders: A systematic review of neurobiological, clinical and pharmacological aspects across the lifespan. *Current Medicinal Chemistry*, 26(38), 6942-6969. https://doi.org/10.2174/09298773266661908190513610

Mulder, N. & Lagan, B. M. (2017). Perceived determinants to alcohol consumption and misuse: A survey of university students. *Perspectives in Public Health*, 137(6), 326-336. https://doi.org/10.1177/1757913917710569

Müller, U., Steffenhagen, N., Regenthal, R., & Bublak, P. (2004). Effects of modafinil on working memory processes in humans. *Psychopharmacology*, 171(1-2), 161-169. https://doi.org/10.1007/s00213-004-1926-3

Murphy, D., Bailey, K., Stone, M., & Wirshing, W. C. (2008). Addictive potential of quetiapine. *The American Journal of Psychiatry*, 165(7), 918. https://doi.org/10.1176/appi.ajp.2008.08020277

Musshoff, F., Madea, B., & Beike, J. (2000). Hallucinogenic mushrooms on the German market - Simple instructions for examination and identification. *Forensic Science International*, 113(1-3), 389-395. https://doi.org/10.1016/S0379-0738(00)00211-5

National Committee on Effective Ethics Committee for Health and Life Sciences, CCNE. (2013). Opinion nº 122. The use of biomedical techniques for “neuroenhancement” in healthy individuals: Ethical issues. https://www.ccne-ethique.fr/sites/default/files/publications/ccneavis.ndeg122eng.pdf

National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK. (2012). LiverTox: Clinical and research information on drug-induced liver injury.

Nehlig, A. (2010). Is caffeine a cognitive enhancer? *Journal of Alzheimer’s Disease*: JAD, 20 Suppl 1, S85-S94. https://doi.org/10.3233/JAD-2010-091315

Nichols, D. E. (1986). Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: Entactogens. *Journal of Psychoactive Drugs*, 18(4), 305-313. https://doi.org/10.1080/02791072.1986.10472362

Nichols, D. E. (2004). Hallucinogens. *Pharmacology & Therapeutics*, 101(2), 131-181. https://doi.org/10.1016/j.pharmthera.2003.11.002

Normann, C., & Berger, M. (2008). Neuroenhancement: Status quo and perspectives. *European Archives of Psychiatry and Clinical Neuroscience*, 258 Suppl 5, 110-114. https://doi.org/10.1007/s00406-008-0522-2

Nutt, D. (1999). Alcohol and the brain. Pharmacological insights for psychiatrists. *The British Journal of Psychiatry: The Journal of Mental Science*, 175, 114-119. https://doi.org/10.1192/bjp.175.2.114

Olff, M., Frijling, J. L., Kuziansky, L. D., Bradley, B., Ellenbogen, M. A., Cardoso, C., Bartz, J. A., Yee, J. R., & van Zuiden, M. (2013). The role of oxytocin in social bonding, stress regulation and mental health: An update on the moderating effects of context and interindividual differences. *Psychoneuroendocrinology*, 38(9), 1883-1894. https://doi.org/10.1016/j.psyneuen.2013.06.019

Oliver, W., McGuffey, G., Westrick, S. C., Jungnickel, P. W., & Correia, C. J. (2014). Alcohol use behaviors among pharmacy students. *American Journal of Pharmaceutical Education*, 78(2), 30. https://doi.org/10.5684/ajpe78230

Olla, P., Ryalkuli, N., Hurtubise, J. L., Bartol, S., Foote, R., Cutter, L., Abeare, K., McVinnie, N., Sabelli, A. G., Hastings, M., & Erdodi, L. A. (2019). Short-term effects of cannabis consumption on cognitive performance in medical cannabis patients. *Applied Neuropsychology. Adult*, 1-11. Advance online publication. https://doi.org/10.1080/2327095.2019.1681424

Osmond, H. (1957). A review of the clinical effects of psychotomimetic agents. *Annals of the New York Academy of Sciences*, 663(3), 418-434. https://doi.org/10.1111/j.1749-6632.1957.tb40738.x

Outram, S. M. (2010). The use of methylphenidate among students: The future of enhancement? *Journal of Medical Ethics*, 36(4), 198-202. https://doi.org/10.1136/jme.2009.034421

Palamar, J. J., & Le, A. (2017). Discordant reporting of nonmedical amphetamine use among Adderall-using high school seniors in the US. *Drug and Alcohol Dependence*, 181, 208-212. https://doi.org/10.1016/j.drugalcdep.2017.09.033

Panes, A., Pariente, A., Bénard-Laribière, A., Lassalle, R., Dureau-Pourcin, C., Lorrain, S., Tourier, M., & Fourrier-Réglat, A. (2020). Use of benzodiazepines and z-drugs not compliant with guidelines and associated factors: A population-based study. *European Archives of Psychiatry and Clinical Neuroscience*, 270(1), 3-10. https://doi.org/10.1007/s00406-018-0966-3

Papasett, E., Farré, M., Pérez-Mañá, C., Torrens, M., Ventura, M., Pujadas, M., de la Torre, R., & González, D. (2018). Acute pharmacological effects of 2C-B in humans: An observational study. *Frontiers in Pharmacology*, 9, 206. https://doi.org/10.3389/fphar.2018.00206

Papasett, E., Olesi, E., Pérez-Mañá, C., Torrens, M., Gríffel, M., Ventura, M., Pozo, O. J., de Sousa Fernandes Perna, E. B., Ramaekers, J. G., de la Torre, R., & Farré, M. (2020). Acute effects of 2C-E in humans: An observational study. *Frontiers in Pharmacology*, 11, 233. https://doi.org/10.3389/fphar.2020.00233

Partridge, B., Bell, S., Lucke, J., & Hall, W. (2013). Australian university students’ attitudes towards the use of prescription stimulants as cognitive enhancers: Perceived patterns of use, efficacy and safety. *Drug and Alcohol Review*, 32(3), 295-302. https://doi.org/10.1111/dar.12005

Perkin, J. E., Wilson, W. J., Schuster, K., Rodríguez, J., & Allen-Chabot, A. (2002). Prevalence of nonvitamin, nonmineral supplement usage among university students. *Journal of the American Dietetic Association*, 102(3), 412-414. https://doi.org/10.1016/s0002-8223(02)90906-9

Pertwee, R. (2014). *Handbook of Cannabis*. Oxford University Press.

Piccinini, A., Veltri, A., Marazziti, D., Mucci, F., Cozzi, A., & Pageat, P. (2018). Human appeasing pheromone (HAP) influence on behavior and psychopathological residual symptoms of patients with complex psychiatric disorders. *Clinical Case Reports*, 6(4), 664-668. https://doi.org/10.1002/crr3.1348

Pies, R. (2009). Should psychiatrists use atypical antipsychotics to treat nonpsychotic anxiety? *Psychiatry (Edgmont (Pa. Township))*, 6(6), 29-37.

Pieters, T., & Snelders, S. (2009). Psychotropic drug use: Between healing and enhancing the mind. *Neuroethics*, 2, 63-73. https://doi.org/10.1007/s12152-009-9033-0

Pokorny, T., Preller, K. H., Kometer, M., Dziobek, I., & Vollenweider, F. X. (2017). Effect of psilocybin on empathy and moral decision-making. *The International Journal of Neuropsychopharmacology*, 20(9), 747-757. https://doi.org/10.1093/ijnp/pqx047

Popovic, D., Vieta, E., Fornaro, M., & Perugi, G. (2015). Cognitive tolerability following successful long term treatment of major depression and anxiety disorders with SSRI antidepressants. *Journal of Affective Disorders*, 173, 211-215. https://doi.org/10.1016/j.jad.2014.11.008

Pratt, L. A., Brody, D. J., & Gu, Q. (2017). Antidepressant use among persons aged 12 and over: United States, 2011-2014. *NCHS Data Brief*, (283), 1-8

Preti, G., Wysocki, C. J., Barnhart, K. T., Sondheim, S. J., & Leyden, J. J. (2003). Male axillary extracts contain pheromones that affect pulsatile secretion of luteinizing hormone.
the role of beliefs in moral judgments. *Proceedings of the National Academy of Sciences of the United States of America*, 107(15), 6753-6758. https://doi.org/10.1073/pnas.0914826107

Zaninotto, A. L., Bueno, O. F., Pradella-Hallinan, M., Tufik, S., Rusted, J., Stough, C., & Pompeia, S. (2009). Acute cognitive effects of donepezil in young, healthy volunteers. *Human Psychopharmacology*, 24(6), 453-464. https://doi.org/10.1002/hup.1044

Zaninotto, A. L., Bueno, O. F., Pradella-Hallinan, M., Tufik, S., Rusted, J., Stough, C., & Pompeia, S. (2009). Acute cognitive effects of donepezil in young, healthy volunteers. *Human Psychopharmacology*, 24(6), 453-464. https://doi.org/10.1002/hup.1044

Zoladz, P. R., Campbell, A. M., Park, C. R., Schaefer, D., Danysz, W., & Diamond, D. M. (2006). Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane. *Pharmacology, Biochemistry, and Behavior*, 83(2), 298-306. https://doi.org/10.1016/j.pbb.2006.08.011